<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Braz J Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Braz J Psychiatry</journal-id>
<journal-id journal-id-type="publisher-id">bjp</journal-id>
<journal-title-group>
<journal-title>Revista Brasileira de Psiquiatria</journal-title>
</journal-title-group>
<issn pub-type="ppub">1516-4446</issn>
<issn pub-type="epub">1809-452X</issn>
<publisher>
<publisher-name>Associação Brasileira de Psiquiatria</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30328963</article-id>
<article-id pub-id-type="pmc">6781690</article-id>
<article-id pub-id-type="doi">10.1590/1516-4446-2018-0005</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Anxiolytic properties of compounds that counteract oxidative stress, neuroinflammation, and glutamatergic dysfunction: a review</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Santos</surname>
<given-names>Patrícia</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Herrmann</surname>
<given-names>Ana P.</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0330-0741</contrib-id>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Elisabetsky</surname>
<given-names>Elaine</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9922-2863</contrib-id>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Piato</surname>
<given-names>Angelo</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5109-7306</contrib-id>
</contrib>
</contrib-group>
<aff>Programa de Pós-Graduação em Farmacologia e Terapêutica, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil</aff>
<author-notes>
<corresp id="cor1">Correspondence: Angelo Piato, Programa de Pós-Graduação em Farmacologia e Terapêutica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Av. Sarmento Leite, 500, sala 305, CEP 90050-170, Porto Alegre, RS, Brazil. E-mail: <email>angelopiato@ufrgs.br</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>11</day>
<month>10</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<season>Mar-Apr</season>
<year>2019</year>
</pub-date>
<volume>41</volume>
<issue>2</issue>
<fpage>168</fpage>
<lpage>178</lpage>
<history>
<date date-type="received">
<day>25</day>
<month>9</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>31</day>
<month>1</month>
<year>2018</year>
</date>
</history>
<permissions>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
<license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Objective:</title>
<p>Anxiety disorders are highly prevalent and the efficacy of the available anxiolytic drugs is less than desired. Adverse effects also compromise patient quality of life and adherence to treatment. Accumulating evidence shows that the pathophysiology of anxiety and related disorders is multifactorial, involving oxidative stress, neuroinflammation, and glutamatergic dysfunction. The aim of this review was to evaluate data from animal studies and clinical trials showing the anxiolytic effects of agents whose mechanisms of action target these multiple domains.</p>
</sec>
<sec>
<title>Methods:</title>
<p>The PubMed database was searched for multitarget agents that had been evaluated in animal models of anxiety, as well as randomized double-blind placebo-controlled clinical trials of anxiety and/or anxiety related disorders.</p>
</sec>
<sec>
<title>Results:</title>
<p>The main multitarget agents that have shown consistent anxiolytic effects in various animal models of anxiety, as well in clinical trials, are agomelatine, N-acetylcysteine (NAC), and omega-3 fatty acids. Data from clinical trials are preliminary at best, but reveal good safety profiles and tolerance to adverse effects.</p>
</sec>
<sec>
<title>Conclusion:</title>
<p>Agomelatine, NAC and omega-3 fatty acids show beneficial effects in clinical conditions where mainstream treatments are ineffective. These three multitarget agents are considered promising candidates for innovative, effective, and better-tolerated anxiolytics.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Anxiety</kwd>
<kwd>agomelatine</kwd>
<kwd>N-acetylcysteine</kwd>
<kwd>omega-3 fatty acids</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Anxiety has been defined as a state of high arousal and enhanced vigilance in the absence of immediate threat.<xref ref-type="bibr" rid="B01">1</xref> It is characterized by subjective experiences (such as persistent worry and tension) in addition to physiological changes (such as sweating and increased heart rate). Though healthy individuals may present sporadic anxiety, it becomes pathological if persistent, disruptive, and disproportionate.<xref ref-type="bibr" rid="B02">2</xref> Anxiety disorders have global lifetime prevalence rates as high as 28%,<xref ref-type="bibr" rid="B03">3</xref> and include social phobia, panic disorder, agoraphobia, and generalized anxiety disorder (GAD).<xref ref-type="bibr" rid="B04">4</xref> Though obsessive-compulsive disorders (OCD) and posttraumatic stress disorder (PTSD) present marked anxiety symptoms, the DSM-5 categorizes these conditions as obsessive-compulsive and related disorders and trauma and stressor-related disorders, respectively.</p>
<p>In addition to drug therapy, the current treatment of anxiety disorders involves lifestyle interventions, such as physical exercise and mindfulness-based stress reduction, as well as psychological interventions, such as cognitive behavioral therapy, which are difficult to implement. The main drug classes used to treat anxiety disorders are GABAergic or serotonergic agents, including benzodiazepines (BZD), 5-HT<sub>1A</sub> serotonin receptor agonists, and selective serotonin reuptake inhibitors (SSRIs).<xref ref-type="bibr" rid="B05">5</xref> Unfortunately, however, not all patients respond to the available medications.<xref ref-type="bibr" rid="B06">6</xref> Moreover, BZDs and SSRIs are associated with unwanted adverse effects, including sedation, memory deficits, dependence, withdrawal syndrome, sexual dysfunction, and weight gain.<xref ref-type="bibr" rid="B05">5</xref> While these adverse effects decrease adherence to treatment, the better-tolerated 5-HT<sub>1A</sub> agonist buspirone has the slowest onset of action and its efficacy is limited to GAD.<xref ref-type="bibr" rid="B07">7</xref>,<xref ref-type="bibr" rid="B08">8</xref>
</p>
<p>Despite its high prevalence, few effective therapeutic targets have been identified for anxiety disorders. The expectation that highly selective agents acting on specific molecular targets would yield better and safer psychiatric drugs has not yet been met.<xref ref-type="bibr" rid="B09">9</xref> A newer approach involving multi-targeted agents <xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref> recognizes the complex pathophysiology underlying psychiatric disorders. In anxiety disorders, oxidative stress,<xref ref-type="bibr" rid="B12">12</xref>
<xref ref-type="bibr" rid="B13">
</xref>-<xref ref-type="bibr" rid="B14">14</xref> neuroinflammation,<xref ref-type="bibr" rid="B15">15</xref> and glutamatergic hyperactivity<xref ref-type="bibr" rid="B16">16</xref>
<xref ref-type="bibr" rid="B17">
</xref>-<xref ref-type="bibr" rid="B18">18</xref> are now recognized as key contributing factors.</p>
<sec>
<title>Anxiety and neurochemical damage</title>
<p>Glutamatergic hyperactivity, a key feature in brain injuries, triggers a complex chain of events, including oxidative stress, mitochondrial dysfunction, and cellular signaling that result in inflammatory response and/or cell death.<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref> Since glutamatergic hyperactivity is characteristic of anxiety,<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref> oxidative stress and neuroinflammation are relevant.</p>
<p>Abnormalities in glutamate neurotransmission are among the biological mechanisms underlying stress response and anxiety disorders.<xref ref-type="bibr" rid="B17">17</xref> Anxiety disorders seem to result from a hyperactive glutamatergic system deregulating inhibitory/excitatory balance in the brain.<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B18">18</xref> Metabotropic glutamatergic 2/3 (mGlu<sub>2/3</sub>) receptors stand out as a potential target for anxiety-modulating drugs (Pitsikas).<xref ref-type="bibr" rid="B16">16</xref> Presynaptically located, mGlu<sub>2/3</sub> receptors are present in several brain areas where glutamate hyperactivity is associated with anxiety, including the cortex, thalamus, striatum, amygdala, and hippocampus.<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref> The activation of mGlu<sub>2/3</sub> receptors limits neuronal glutamate release,<xref ref-type="bibr" rid="B23">23</xref> and agonists of such receptors show anxiolytic activity in diverse animal models of anxiety.<xref ref-type="bibr" rid="B16">16</xref>
</p>
<p>An association between anxiety and oxidative stress has been documented in rodents and humans. Hovatta et al.<xref ref-type="bibr" rid="B24">24</xref> found a positive correlation between glyoxalase I and glutathione reductase I gene expression and anxiety phenotypes on stress-related behaviors in isogenic mice. Overexpression of the glyoxalase I gene has also been reported for naturally anxious mice.<xref ref-type="bibr" rid="B25">25</xref> Bouayed et al.<xref ref-type="bibr" rid="B26">26</xref> reported a positive correlation between markers of peripheral oxidative stress and anxious behavior in mice. Increased anxiety-like behavior accompanied by oxidative stress has been documented in rodents exposed to psychological stress,<xref ref-type="bibr" rid="B27">27</xref> chronic restraint stress,<xref ref-type="bibr" rid="B28">28</xref> and oxidative stress inducers.<xref ref-type="bibr" rid="B29">29</xref>-<xref ref-type="bibr" rid="B31">31</xref> Changes in antioxidant defenses and elevated lipid peroxidation products have been reported in GAD,<xref ref-type="bibr" rid="B32">32</xref>-<xref ref-type="bibr" rid="B34">34</xref> OCD,<xref ref-type="bibr" rid="B35">35</xref>
<xref ref-type="bibr" rid="B36">
</xref>
<xref ref-type="bibr" rid="B37">
</xref>
<xref ref-type="bibr" rid="B38">
</xref>-<xref ref-type="bibr" rid="B39">39</xref> panic disorder,<xref ref-type="bibr" rid="B40">40</xref> and social phobia.<xref ref-type="bibr" rid="B41">41</xref>,<xref ref-type="bibr" rid="B42">42</xref> Anxious women were found to have a lower total antioxidant capacity in the blood than controls.<xref ref-type="bibr" rid="B43">43</xref>
</p>
<p>Associations between deregulation of the hypothalamic pituitary adrenal axis (HPA) and anxiety disorders are widely recognized, resulting in changes in the levels of pro- and anti-inflammatory cytokines and cortisol.<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B44">44</xref> Inflammatory cytokines and immune cells can access the brain and alter behavior, including the synthesis, release, and reuptake of neurotransmitters such as glutamate, serotonin, and dopamine, which are affected by cytokines and their signaling pathways.<xref ref-type="bibr" rid="B45">45</xref> The kynurenine pathway is also activated by cytokines, generating neuroactive metabolites that influence dopamine and glutamate transmission and, by depleting tryptophan, regulate the synthesis of serotonin.<xref ref-type="bibr" rid="B45">45</xref>
</p>
<p>Increased peripheral cytokine expression is associated with increased anxiety in mice.<xref ref-type="bibr" rid="B46">46</xref>,<xref ref-type="bibr" rid="B47">47</xref> Mice overexpressing interleukin (IL)-6 or tumor necrosis factor (TNF) exhibit an anxiogenic phenotype.<xref ref-type="bibr" rid="B48">48</xref>,<xref ref-type="bibr" rid="B49">49</xref> Several human studies have also shown a correlation between anxiety, neuroinflammation, and the immune system.<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B44">44</xref> Injection of the immune activator lipopolysaccharide (LPS) induced anxiety symptoms in normal volunteers,<xref ref-type="bibr" rid="B50">50</xref> and a positive correlation between anxiety and increased levels of inflammatory markers (such as TNF-α and IL-6) has been repeatedly documented in anxiety disorders.<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B43">43</xref>,<xref ref-type="bibr" rid="B51">51</xref>,<xref ref-type="bibr" rid="B52">52</xref>
</p>
<p>Strategies to minimize and/or counteract the damage resulting from these accompanying neurochemical processes may lead to innovation in the field of anxiolytic drug research. As a key step in translational research is target validation, the aim of this study is to review drug candidates known to counteract oxidative stress, neuroinflammation, and glutamatergic hyperfunction that have undergone preclinical and clinical analyses relevant to anxiety disorders.</p>
</sec>
</sec>
<sec sec-type="methods">
<title>Methods</title>
<p>The PubMed database was searched through March 2017. The search strategy used successive combinations of the following terms (compounds whose multi-target mechanisms of action have been well-established in the literature, including modulation of oxidative stress and/or neuroinflammation and/or glutamate hyperactivity): ascorbic acid, vitamin C, vitamin A, vitamin E, tocopherol, vitamin D, polyphenols, flavonoids, mGlu<sub>2/3</sub> modulator, melatonin, agomelatine, N-acetylcysteine, omega-3 fatty acids, omega-3 polyunsaturated fatty acids (PUFA) AND anxiety. The results were initially limited to clinical trials. The criterion for a compound’s inclusion in this review was evidence of anxiolytic effects in both randomized double-blind placebo-controlled clinical trials and animal models. When no such studies were found for a given compound, it was excluded from further analysis. For compounds that had been tested in clinical trials, we also carried out searches for the compound AND each of these conditions (which are classified as anxiety disorders or have a strong relation with anxiety-related symptoms): generalized anxiety disorder, social phobia, specific phobia, panic disorder, obsessive-compulsive disorder, posttraumatic stress disorder, trichotillomania, nail biting, and excoriation (skin-picking) disorder. The publications were assessed for relevance to the selected topics. The search was limited to texts in English. To select articles for inclusion, all the abstracts found using the search criteria were read.</p>
</sec>
<sec>
<title>Results and discussion</title>
<p>We found that agomelatine, N-acetylcysteine (NAC), and omega-3 PUFA are the main agents fitting the inclusion criteria that have demonstrated antioxidant, anti-inflammatory, and glutamatergic effects.</p>
<sec>
<title>Agomelatine</title>
<p>Agomelatine, a synthetic analog of melatonin, is a high-affinity agonist of MT<sub>1</sub> and MT<sub>2</sub> melatonin receptors.<xref ref-type="bibr" rid="B53">53</xref>,<xref ref-type="bibr" rid="B54">54</xref> Agomelatine antagonizes 5-HT<sub>2C</sub> serotonin receptors, an effect thought to be involved in its anxiolytic effects.<xref ref-type="bibr" rid="B55">55</xref> Agomelatine also modulates glutamate neurotransmission in regions associated with mood and cognition, such as the prefrontal and frontal cortex,<xref ref-type="bibr" rid="B55">55</xref> the hippocampus, and the amygdala.<xref ref-type="bibr" rid="B56">56</xref> In rats submitted to prenatal restraint stress, agomelatine blocked the stress-induced glutamate release in the prefrontal cortex<xref ref-type="bibr" rid="B57">57</xref> and regularized glutamate release and the expression of mGlu<sub>2/3</sub> receptor mRNA in the hippocampus.<xref ref-type="bibr" rid="B58">58</xref>
</p>
<p>Agomelatine decreased lipid peroxidation levels and nitrite contents in the brains of mice submitted to chemically induced seizures<xref ref-type="bibr" rid="B59">59</xref> and protected cultured PC-12 neuronal cells from cytosolic reactive oxygen species production, as well as increased glutathione.<xref ref-type="bibr" rid="B60">60</xref>
</p>
<p>Agomelatine was able to reduce LPS-induced upregulation of proinflammatory cytokines IL-6 and IL1-β both within and outside rat brains. These effects were accompanied by inhibition of nuclear factor kappa B (NF-κB) translocation and microglia activation.<xref ref-type="bibr" rid="B61">61</xref> Microglia are resident macrophages normally present in the healthy brain that perform active tissue scanning and can respond quickly to any microenvironment change.<xref ref-type="bibr" rid="B62">62</xref> Agomelatine also modified the expression of enzymes associated with the kynurenine pathway, possibly protecting the brain from the neurotoxic consequences of the conversion of kynurenine to quinolinic acid, an N-methyl-D-aspartate (NMDA) receptor agonist.<xref ref-type="bibr" rid="B61">61</xref>
</p>
<p>Though the antidepressant properties of agomelatine have been better characterized,<xref ref-type="bibr" rid="B63">63</xref> its anxiolytic effects have been reported in different animal models<xref ref-type="bibr" rid="B58">58</xref>,<xref ref-type="bibr" rid="B64">64</xref>
<xref ref-type="bibr" rid="B65">
</xref>-<xref ref-type="bibr" rid="B66">66</xref> (<xref ref-type="table" rid="t01">Table 1</xref>). In most animal studies, agomelatine’s anxiolytic effects were documented after acute administration. However, Morley-Fletcher et al. reported that agomelatine administered for 3 or 6 weeks prevented prenatal restraint stress (in the elevated plus-maze) as well as reversed the reduced hippocampal levels of mGlu<sub>2/3</sub> and mGlu<sub>5</sub> receptors in rats.<xref ref-type="bibr" rid="B58">58</xref> These effects were restricted to rats submitted to restraint stress, which suggests that agomelatine modulation of mGlu<sub>2/3</sub> receptors may be especially relevant in stressed subjects.</p>
<p>Most of the available clinical data on agomelatine as an anxiolytic refer to GAD patients and were published by the same group. The first clinical trial was published in 2008 (<xref ref-type="table" rid="t02">Table 2</xref>), in which GAD patients (comorbidity free) were randomized to receive agomelatine or placebo for 12 weeks.<xref ref-type="bibr" rid="B65">65</xref> This randomized double-blind placebo controlled trial (RDBCT) revealed that agomelatine (25-50 mg/day) was superior to placebo in the primary outcome (Hamilton Anxiety Rating Scale), as well as secondary outcome measures (clinical response, insomnia, and associated disability). In this study, agomelatine was well tolerated and discontinuation symptoms were lower in agomelatine than placebo patients.<xref ref-type="bibr" rid="B80">80</xref> An open-label study with agomelatine 25-50 mg/day for 16 weeks followed by a multicenter RDBCT (with the same doses of agomelatine) for 26 weeks was conducted to evaluate long-term tolerability to agomelatine and its efficacy in preventing relapse. The results showed that agomelatine was well tolerated and superior to placebo in preventing relapse.<xref ref-type="bibr" rid="B81">81</xref> A third trial compared agomelatine with escitalopram and placebo. The multicenter RDBCT showed that agomelatine and escitalopram were comparable regarding improved symptomatology, but escitalopram had a higher incidence of adverse events than placebo.<xref ref-type="bibr" rid="B82">82</xref> A recent trial evaluated the minimal effective optimal dose of agomelatine in GAD patients: the 12-week multicenter RDBCT showed that 10 and 25 mg/kg are better than placebo, and the best response was obtained with 25 mg.<xref ref-type="bibr" rid="B83">83</xref>
</p>
<p>Data on other anxiety disorders are very limited and present too many confounding factors to allow meaningful conclusions.<xref ref-type="bibr" rid="B99">99</xref> Stein et al. reviewed data from three placebo-controlled short-term trials<xref ref-type="bibr" rid="B100">100</xref>
<xref ref-type="bibr" rid="B101">
</xref>-<xref ref-type="bibr" rid="B102">102</xref> and three comparative studies of agomelatine vs. the SSRI antidepressants venlafaxine,<xref ref-type="bibr" rid="B103">103</xref> fluoxetine,<xref ref-type="bibr" rid="B104">104</xref> and sertraline<xref ref-type="bibr" rid="B105">105</xref> in major depression patients with anxiety symptoms, finding that agomelatine had a greater effect on anxiety symptoms than placebo or antidepressants.<xref ref-type="bibr" rid="B106">106</xref>
</p>
<p>Adverse events reported with agomelatine are mostly perceived as mild to moderate and include headache, dizziness, somnolence, fatigue, and gastrointestinal symptoms.<xref ref-type="bibr" rid="B107">107</xref> Elevation of liver transaminase levels and rare cases of hepatic failure were seen only with 50 mg/day.<xref ref-type="bibr" rid="B107">107</xref> The use of agomelatine was not associated with discontinuation symptoms,<xref ref-type="bibr" rid="B108">108</xref>,<xref ref-type="bibr" rid="B109">109</xref> a relevant aspect considering its beneficial effects on sleep disturbances observed in patients with depression and/or anxiety.<xref ref-type="bibr" rid="B80">80</xref>,<xref ref-type="bibr" rid="B82">82</xref>
</p>
</sec>
<sec>
<title>NAC</title>
<p>NAC is a precursor of cysteine (required for the production of the primary endogenous antioxidant glutathione) and can directly sequester oxidants.<xref ref-type="bibr" rid="B110">110</xref> NAC supplementation results in additional cysteine, which activates the cystine/glutamate antiporter (also called x[c]-system), predominantly expressed by astrocytes in the brain. The cysteine dimer, cystine, is taken up by astrocytes and exchanged for glutamate, which activates mGluR<sub>2/3</sub> receptors on presynaptic neurons and reduces the synaptic release of glutamate.<xref ref-type="bibr" rid="B110">110</xref>
</p>
<p>NAC has anti-inflammatory properties as result of multiple mechanisms. Through its direct antioxidant effect and as a glutathione (GSH) precursor, NAC inhibits the activation of the proinflammatory transcription factor NF-κB, which downregulates the expression of several proinflammatory genes.<xref ref-type="bibr" rid="B111">111</xref>
<xref ref-type="bibr" rid="B112">
</xref>-<xref ref-type="bibr" rid="B113">113</xref> Microglia inhibition also seems to be important in NAC’s ability to reduce neuroinflammation.<xref ref-type="bibr" rid="B114">114</xref>,<xref ref-type="bibr" rid="B115">115</xref> Therefore, by stimulating GSH synthesis and regulating the cystine/glutamate antiporter, glutamate excitotoxicity, and oxidative stress, NAC inhibits microglia, macrophage activation, and the production of cytokines and oxidative species.<xref ref-type="bibr" rid="B114">114</xref>,<xref ref-type="bibr" rid="B116">116</xref>
</p>
<p>The anti-inflammatory properties of NAC have been documented in animal models of ischemic and traumatic brain injury,<xref ref-type="bibr" rid="B117">117</xref>
<xref ref-type="bibr" rid="B118">
</xref>-<xref ref-type="bibr" rid="B119">119</xref> LPS-induced pulmonary edema,<xref ref-type="bibr" rid="B120">120</xref> and lethal endotoxemia.<xref ref-type="bibr" rid="B121">121</xref> In humans, NAC has reduced lung inflammation (Blackwell et al.<xref ref-type="bibr" rid="B122">122</xref>) decreased proinflammatory cytokines in burn<xref ref-type="bibr" rid="B123">123</xref> and dialysis patients,<xref ref-type="bibr" rid="B124">124</xref> and caused a reduction of proinflammatory cytokines, as well as shown antioxidant effects in cardiac injury after aortic aneurysm repair.<xref ref-type="bibr" rid="B125">125</xref>
</p>
<p>Egashira et al. found that acute NAC (but not α-tocopherol) inhibited marble-burying behavior in mice (<xref ref-type="table" rid="t01">Table 1</xref>), suggesting that this anxiolytic-like effect is related to glutamate modulation rather than antioxidant effects.<xref ref-type="bibr" rid="B67">67</xref> Chen et al. showed that NAC reversed valproate-induced social interaction deficit and anxiety-like behavior in rats (considered an experimental model of autism). The effects were that mGlu<sub>2/3</sub> receptor antagonist LY341495 blocked dependent mGLU<sub>2/3</sub> receptors. Accordingly, NAC also reduced enhanced presynaptic excitatory neurotransmission to normal levels in the amygdala of valproate-exposed rats.<xref ref-type="bibr" rid="B68">68</xref> NAC prevented rhythm disruption-induced anxiety in mice.<xref ref-type="bibr" rid="B69">69</xref> The anxiolytic effects of NAC have also been documented in the light/dark model and in stress-induced anxiety behavior in zebrafish,<xref ref-type="bibr" rid="B70">70</xref> as well as in the hole-board test, the light/dark model, the open field test, social interaction, and stress-induced hyperthermia in mice.<xref ref-type="bibr" rid="B71">71</xref> One report suggested that NAC may have anxiogenic properties, but this conclusion is questionable since it was based only on decreased time spent in the center of an open field, which was also accompanied by decreased locomotion.<xref ref-type="bibr" rid="B84">84</xref>
</p>
<p>Very few studies have been designed to evaluate the specific effects of NAC in patients diagnosed with an anxiety disorder. Back et al. conducted a study with NAC in veterans diagnosed with comorbid PTSD and substance use disorder (SUD) in which the patients were treated with NAC or placebo, along with group cognitive-behavioral therapy. NAC decreased self-reported and clinician-rated PTSD symptoms, and the symptoms remained significantly lower after the drug was discontinued at one-month of follow-up. Patients receiving NAC also reported decreased cravings.<xref ref-type="bibr" rid="B88">88</xref>
</p>
<p>NAC has been evaluated in obsessive-compulsive and related disorders where anxiety is a key component. An RDBCT conducted by Grant et al. revealed significant improvement in trichotillomania patients after 12 weeks of treatment<xref ref-type="bibr" rid="B126">126</xref>; this result was substantiated by a number of case reports.<xref ref-type="bibr" rid="B127">127</xref>
<xref ref-type="bibr" rid="B128">
</xref>-<xref ref-type="bibr" rid="B129">129</xref> In pediatric trichotillomania patients, an RDBCT found no significant reduction in hair pulling compared to placebo<xref ref-type="bibr" rid="B130">130</xref>; in this trial, the authors suggested that the improvement was associated with psychoeducation about trichotillomania rather than drug treatment, since significant improvement in several measures of hair pulling was observed regardless of treatment time. A series of case reports showed that NAC is effective against excoriation disorder,<xref ref-type="bibr" rid="B127">127</xref>,<xref ref-type="bibr" rid="B131">131</xref>
<xref ref-type="bibr" rid="B132">
</xref>-<xref ref-type="bibr" rid="B133">133</xref> and an RDBCT concluded that NAC significantly reduced skin-picking symptoms.<xref ref-type="bibr" rid="B89">89</xref> Berk et al. found a reduced nail biting frequency in three patients enrolled in a bipolar disorder treatment protocol with NAC.<xref ref-type="bibr" rid="B134">134</xref> Ghanizadeh et al.’s finding that NAC decreases nail biting in the short, but not the long term is somewhat questionable considering the lower dose and shorter treatment time used in their RDBCT compared to the case reports.<xref ref-type="bibr" rid="B86">86</xref>
</p>
<p>It has been reported that NAC has beneficial effects in children, adolescents, and adults with OCD.<xref ref-type="bibr" rid="B135">135</xref>,<xref ref-type="bibr" rid="B136">136</xref> Afshar et al. conducted an RDBCT with NAC as an add-on treatment in OCD patients refractory to SSRIs, finding that NAC improved Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) and Clinical Global Impression-Severity of Illness (CGI-S) scores, but not those on the Clinical Global Impression–Improvement Scale (CGI-I); full responders at the end of the study were significantly higher than placebo.<xref ref-type="bibr" rid="B85">85</xref> Sarris et al. conducted an RDBCT using NAC as add-on treatment (mainly to SSRIs) in OCD patients; the primary outcome measure was the Y-BOCS, conducted every 4 weeks. At week 12 there was a significant reduction in Y-BOCS score, but the difference dissipated at week 16.<xref ref-type="bibr" rid="B87">87</xref> A third RDBCT was performed with moderate-to-severe OCD patients, randomized to receive fluvoxamine plus placebo or fluvoxamine plus NAC. NAC showed a significant effect on Y-BOCS score.<xref ref-type="bibr" rid="B90">90</xref>
</p>
</sec>
<sec>
<title>Omega-3</title>
<p>Adequate dietary levels of PUFA, including omega-3 fatty acids, are essential for health since they are important components of cholesterol esters and phospholipids in the neuronal cell membrane. Changes in the composition of these membrane phospholipids can affect the regulation of neurotransmitter release, receptors, ion channels, and enzyme activity.<xref ref-type="bibr" rid="B137">137</xref>,<xref ref-type="bibr" rid="B138">138</xref> Omega-3 and omega-6 PUFAs are cleaved from membrane phospholipids and converted via different pathways to mediators that have opposing effects: arachidonic acid mediators are derived from omega-6 fatty acids and are proinflammatory, while mediators derived from omega-3 fatty acids have anti-inflammatory effects. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are the two main types of omega-3 PUFA, and fish oil is their main dietary source. It has been suggested that EPA may play a role in brain function by counteracting arachidonic acid-mediated signaling, decreasing immune-inflammatory responses mediated by omega-6 derived eicosanoids, which have been linked to the pathophysiology of anxiety and other mental disorders.<xref ref-type="bibr" rid="B92">92</xref>,<xref ref-type="bibr" rid="B139">139</xref> Moreover, by inhibiting proinflammatory cytokine secretion, omega-3 may also decrease corticosteroid release from the adrenal gland, reducing the mood-altering effects associated with increased cortisol,<xref ref-type="bibr" rid="B140">140</xref> and hence reducing the impact of cortisol on anxiety.</p>
<p>Several studies have investigated the effects of omega-3 fatty acids in animal models of anxiety (<xref ref-type="table" rid="t01">Table 1</xref>). Most of the rodent studies involved long-term diet supplements with DHA or a combination of EPA and DHA. Carrié et al. used a DHA-supplemented diet in mice previously fed with a semisynthetic balanced diet or a diet deficient in alpha-linolenic acid (ALA) (another type of omega-3 fatty acid) until the age of 8 months. The supplemented diet showed anxiolytic effects, regardless of the previous diet condition, and restored water maze performance, which had been impaired in the ALA deficient diet group.<xref ref-type="bibr" rid="B72">72</xref> Jašarević et al. treated female mice for three generations with an omega-6/omega-3 supplemented diet and found that the male offspring of the third generation showed decreased anxiety-like behavior.<xref ref-type="bibr" rid="B78">78</xref> Rat diets supplemented with different combinations of PUFAs counteracted the anxiogenic effects of intracerebroventricular administered IL-1 beta<xref ref-type="bibr" rid="B73">73</xref>,<xref ref-type="bibr" rid="B74">74</xref> and restraint stress.<xref ref-type="bibr" rid="B75">75</xref>,<xref ref-type="bibr" rid="B77">77</xref> The anxiolytic effect of omega-3 supplementation has also been demonstrated in adult male grey mouse lemurs (<italic>Microcebus murinus</italic>), a nocturnal Malagasy prosimian primate.<xref ref-type="bibr" rid="B76">76</xref>,<xref ref-type="bibr" rid="B79">79</xref>
</p>
<p>Low omega-3 levels in erythrocyte membranes have been observed in patients with anxiety disorders.<xref ref-type="bibr" rid="B141">141</xref>
<xref ref-type="bibr" rid="B142">
</xref>-<xref ref-type="bibr" rid="B143">143</xref> Nevertheless, most trials investigating omega-3 in anxiety focused on anxiety symptoms in different conditions rather than anxiety disorders themselves. In an RDBCT with healthy young adults, Kiecolt-Glaser et al. showed that EPA and DHA supplementation decreased anxiety symptoms and LPS-stimulated production of IL-6.<xref ref-type="bibr" rid="B94">94</xref> Yehuda et al. showed that a mixture of ALA and linolenic acid, given to university students experiencing significant anxiety associated with upcoming exams (test anxiety), improved variables associated with test anxiety (e.g., appetite, mood, concentration, fatigue, academic organization, sleep) and lowered cortisol levels.<xref ref-type="bibr" rid="B91">91</xref> The anxiolytic effects of omega-3 supplementation were found in patients with acute myocardial infarction<xref ref-type="bibr" rid="B96">96</xref> and women diagnosed with premenstrual syndrome (PMS).<xref ref-type="bibr" rid="B97">97</xref> In an RDBCT, Buydens-Branchey &amp; Branchey investigated the effects of a mixture of EPA + DHA supplementation in patients with a history of substance abuse, finding that the supplementation progressively decreased anxiety scores, which remained decreased three months after treatment was discontinued.<xref ref-type="bibr" rid="B138">138</xref> In a subsequent similarly designed RDBCT, the same group showed that increases in circulating omega-3 levels paralleled decreases in anxiety scores.<xref ref-type="bibr" rid="B93">93</xref> Similar results were found with male alcoholic patients in a residential rehabilitation program: this small-sample RDBCT showed that fish oil (a source of omega-3 fatty acids) decreased stress/anxiety ratings and reduced basal levels of cortisol.<xref ref-type="bibr" rid="B95">95</xref> In a placebo-controlled crossover trial, Fux et al. showed that EPA is ineffective as an add-on treatment to SSRI in OCD patients, though the reliability of their results is questionable due to the small sample size and the high placebo response.<xref ref-type="bibr" rid="B144">144</xref> Matsuoka et al. reported that omega-3 supplementation was not superior to placebo for PTSD symptom prevention three months after accidental injury.<xref ref-type="bibr" rid="B145">145</xref> In a cohort of Japanese accident survivors at risk of developing PTSD, the same group reported that short-term supplementation with DHA and EPA lowered heart rates during script-driven imagery and/or resting, whereas the baseline heart rate did not differ from the placebo group.<xref ref-type="bibr" rid="B98">98</xref>
</p>
<p>In addition to the compounds discussed above (agomelatine, NAC, and omega-3 fatty acids), we also found some evidence of anxiolytic effects in clinical trials and animal studies for ascorbic acid (vitamin C) and the mGlu<sub>2/3</sub> receptor agonist LY354740. Although ascorbic acid has presented anxiolytic effects in different animal models in rats,<xref ref-type="bibr" rid="B146">146</xref> mice,<xref ref-type="bibr" rid="B147">147</xref> and zebrafish,<xref ref-type="bibr" rid="B148">148</xref> evidence of its anxiolytic effects in humans is limited. Only one small randomized double-blind placeb-controlled clinical trial (n=42) with ascorbic acid conducted with normal volunteers was found: its results were that ascorbic acid decreased anxiety levels.<xref ref-type="bibr" rid="B149">149</xref> Although studies with LY354740 showed robust anxiolytic activity in several animal models, as well as in a few clinical trials, larger clinical trials were interrupted due to reports of seizures in animal studies.<xref ref-type="bibr" rid="B16">16</xref>
</p>
<p>One limitation of our study is the likely existence of publication bias in this field. Despite the possibility that many negative results concerning this topic may have been deterred from publication, our main goal was to present the available data for compounds with a robust body of evidence.</p>
</sec>
</sec>
<sec>
<title>Conclusion</title>
<p>We reviewed three compounds that may counteract key biochemical correlates of anxiety states. Despite a reasonable body of evidence showing anxiolytic properties, the results show that the clinical data is deficient. Data from clinical trials are more indicative than conclusive, and larger trials specifically designed for anxiety disorders are needed. Nevertheless, the beneficial effect observed in clinical conditions where mainstream treatments are ineffective should not be overlooked.</p>
<p>Regarding safety and tolerability, clinical trials and toxicity studies have shown that agomelatine,<xref ref-type="bibr" rid="B106">106</xref>,<xref ref-type="bibr" rid="B150">150</xref> NAC,<xref ref-type="bibr" rid="B111">111</xref> and omega-3<xref ref-type="bibr" rid="B151">151</xref> were generally well tolerated and free from serious adverse effects. The most common side effects reported were headache, dizziness, somnolence, fatigue, and gastrointestinal symptoms for agomelatine,<xref ref-type="bibr" rid="B150">150</xref> gastrointestinal symptoms, with headache for NAC<xref ref-type="bibr" rid="B111">111</xref> and a fish aftertaste and nausea with omega-3.<xref ref-type="bibr" rid="B140">140</xref>,<xref ref-type="bibr" rid="B151">151</xref>
</p>
<p>In conclusion, due to the prevalence and morbidity of anxiety disorders, the potential translational value of the biochemical basis of anxiety, and the safety profile of these compounds, investment in larger clinical trials seems justified.</p>
</sec>
<sec sec-type="COI-statement">
<title>Disclosure</title>
<p>The authors report no conflict of interest.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>The authors would like to thank the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq; EE, AP) and the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES; PS) for fellowships.</p>
</ack>
<fn-group>
<fn fn-type="other">
<p>
<bold>How to cite this article:</bold> Santos P, Herrmann AP, Elisabetsky E, Piato A. Anxiolytic properties of compounds that counteract oxidative stress, neuroinflammation, and glutamatergic dysfunction: a review. Braz J Psychiatry. 2019;41:168-178. http://dx.doi.org/10.1590/1516-4446-2018-0005</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B01">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davis</surname><given-names>M</given-names></name><name><surname>Walker</surname><given-names>DL</given-names></name><name><surname>Miles</surname><given-names>L</given-names></name><name><surname>Grillon</surname><given-names>C</given-names></name></person-group>
<article-title>Phasic vs sustained fear in rats and humans: role of the extended amygdala in fear vs anxiety</article-title>
<source/>Neuropsychopharmacology
<year>2010</year>
<volume>35</volume>
<fpage>105</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="pmid">19693004</pub-id></element-citation>
</ref>
<ref id="B02">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Calhoon</surname><given-names>GG</given-names></name><name><surname>Tye</surname><given-names>KM</given-names></name></person-group>
<article-title>Resolving the neural circuits of anxiety</article-title>
<source/>Nat Neurosci
<year>2015</year>
<volume>18</volume>
<fpage>1394</fpage>
<lpage>404</lpage>
<pub-id pub-id-type="pmid">26404714</pub-id></element-citation>
</ref>
<ref id="B03">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baxter</surname><given-names>AJ</given-names></name><name><surname>Scott</surname><given-names>KM</given-names></name><name><surname>Vos</surname><given-names>T</given-names></name><name><surname>Whiteford</surname><given-names>HA</given-names></name></person-group>
<article-title>Global prevalence of anxiety disorders: a systematic review and meta-regression</article-title>
<source/>Psychol Med
<year>2013</year>
<volume>43</volume>
<fpage>897</fpage>
<lpage>910</lpage>
<pub-id pub-id-type="pmid">22781489</pub-id></element-citation>
</ref>
<ref id="B04">
<label>4</label>
<element-citation publication-type="book">
<person-group person-group-type="author"><collab>American Psychiatric Association</collab></person-group>
<source/>Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
<publisher-loc>Arlington</publisher-loc>
<publisher-name>American Psychiatric Publishing</publisher-name>
<year>2013</year>
</element-citation>
</ref>
<ref id="B05">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stein</surname><given-names>MB</given-names></name><name><surname>Craske</surname><given-names>MG</given-names></name></person-group>
<article-title>Treating anxiety in 2017: optimizing care to improve outcomes</article-title>
<source/>JAMA
<year>2017</year>
<volume>318</volume>
<fpage>235</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">28679009</pub-id></element-citation>
</ref>
<ref id="B06">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hamner</surname><given-names>MB</given-names></name><name><surname>Robert</surname><given-names>S</given-names></name><name><surname>Frueh</surname><given-names>BC</given-names></name></person-group>
<article-title>Treatment-resistant posttraumatic stress disorder: strategies for intervention</article-title>
<source/>CNS Spectr
<year>2004</year>
<volume>9</volume>
<fpage>740</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">15448585</pub-id></element-citation>
</ref>
<ref id="B07">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cryan</surname><given-names>JF</given-names></name><name><surname>Sweeney</surname><given-names>FF</given-names></name></person-group>
<article-title>The age of anxiety: role of animal models of anxiolytic action in drug discovery</article-title>
<source/>Br J Pharmacol
<year>2011</year>
<volume>164</volume>
<fpage>1129</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="pmid">21545412</pub-id></element-citation>
</ref>
<ref id="B08">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Loane</surname><given-names>C</given-names></name><name><surname>Politis</surname><given-names>M</given-names></name></person-group>
<article-title>Buspirone: what is it all about?</article-title>
<source/>Brain Res
<year>2012</year>
<volume>1461</volume>
<fpage>111</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">22608068</pub-id></element-citation>
</ref>
<ref id="B09">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Griebel</surname><given-names>G</given-names></name><name><surname>Holmes</surname><given-names>A</given-names></name></person-group>
<article-title>50 years of hurdles and hope in anxiolytic drug discovery</article-title>
<source/>Nat Rev Drug Discov
<year>2013</year>
<volume>12</volume>
<fpage>667</fpage>
<lpage>87</lpage>
<pub-id pub-id-type="pmid">23989795</pub-id></element-citation>
</ref>
<ref id="B10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hopkins</surname><given-names>AL</given-names></name></person-group>
<article-title>Network pharmacology: the next paradigm in drug discovery</article-title>
<source/>Nat Chem Biol
<year>2008</year>
<volume>4</volume>
<fpage>682</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="pmid">18936753</pub-id></element-citation>
</ref>
<ref id="B11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Youdim</surname><given-names>MB</given-names></name><name><surname>Buccafusco</surname><given-names>JJ</given-names></name></person-group>
<article-title>Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders</article-title>
<source/>Trends Pharmacol Sci
<year>2005</year>
<volume>26</volume>
<fpage>27</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="pmid">15629202</pub-id></element-citation>
</ref>
<ref id="B12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hassan</surname><given-names>W</given-names></name><name><surname>Silva</surname><given-names>CE</given-names></name><name><surname>Mohammadzai</surname><given-names>IU</given-names></name><name><surname>da Rocha</surname><given-names>JB</given-names></name><name><surname>Landeira-Fernandez</surname><given-names>J</given-names></name></person-group>
<article-title>Association of oxidative stress to the genesis of anxiety: implications for possible therapeutic interventions</article-title>
<source/>Curr Neuropharmacol
<year>2014</year>
<volume>12</volume>
<fpage>120</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="pmid">24669207</pub-id></element-citation>
</ref>
<ref id="B13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ng</surname><given-names>F</given-names></name><name><surname>Berk</surname><given-names>M</given-names></name><name><surname>Dean</surname><given-names>O</given-names></name><name><surname>Bush</surname><given-names>AI</given-names></name></person-group>
<article-title>Oxidative stress in psychiatric disorders: evidence base and therapeutic implications</article-title>
<source/>Int J Neuropsychopharmacol
<year>2008</year>
<volume>11</volume>
<fpage>851</fpage>
<lpage>76</lpage>
<pub-id pub-id-type="pmid">18205981</pub-id></element-citation>
</ref>
<ref id="B14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Salim</surname><given-names>S</given-names></name></person-group>
<article-title>Oxidative stress and psychological disorders</article-title>
<source/>Curr Neuropharmacol
<year>2014</year>
<volume>12</volume>
<fpage>140</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">24669208</pub-id></element-citation>
</ref>
<ref id="B15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Furtado</surname><given-names>M</given-names></name><name><surname>Katzman</surname><given-names>MA</given-names></name></person-group>
<article-title>Neuroinflammatory pathways in anxiety, posttraumatic stress, and obsessive compulsive disorders</article-title>
<source/>Psychiatry Res
<year>2015</year>
<volume>229</volume>
<fpage>37</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="pmid">26296951</pub-id></element-citation>
</ref>
<ref id="B16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pitsikas</surname><given-names>N</given-names></name></person-group>
<article-title>The metabotropic glutamate receptors: potential drug targets for the treatment of anxiety disorders?</article-title>
<source/>Eur J Pharmacol
<year>2014</year>
<volume>723</volume>
<fpage>181</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="pmid">24361306</pub-id></element-citation>
</ref>
<ref id="B17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Riaza Bermudo-Soriano</surname><given-names>C</given-names></name><name><surname>Perez-Rodriguez</surname><given-names>MM</given-names></name><name><surname>Vaquero-Lorenzo</surname><given-names>C</given-names></name><name><surname>Baca-Garcia</surname><given-names>E</given-names></name></person-group>
<article-title>New perspectives in glutamate and anxiety</article-title>
<source/>Pharmacol Biochem Behav
<year>2012</year>
<volume>100</volume>
<fpage>752</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="pmid">21569789</pub-id></element-citation>
</ref>
<ref id="B18">
<label>18</label>
<element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Wierońska</surname><given-names>JM</given-names></name><name><surname>Stachowicz</surname><given-names>K</given-names></name><name><surname>Nowak</surname><given-names>G</given-names></name><name><surname>Pilc</surname><given-names>A</given-names></name></person-group>
<source/>The loss of glutamate-GABA harmony in anxiety disorders
<person-group person-group-type="editor"><name><surname>Kalinin</surname><given-names>V</given-names></name></person-group>
<source/>Anxiety disorders
<publisher-loc>Rijeka</publisher-loc>
<publisher-name>Intech</publisher-name>
<year>2011</year>
<fpage>p. 135</fpage>
<lpage>58</lpage>
</element-citation>
</ref>
<ref id="B19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sattler</surname><given-names>R</given-names></name><name><surname>Tymianski</surname><given-names>M</given-names></name></person-group>
<article-title>Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell death</article-title>
<source/>Mol Neurobiol
<year>2001</year>
<volume>24</volume>
<fpage>107</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="pmid">11831548</pub-id></element-citation>
</ref>
<ref id="B20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Najjar</surname><given-names>S</given-names></name><name><surname>Pearlman</surname><given-names>DM</given-names></name><name><surname>Alper</surname><given-names>K</given-names></name><name><surname>Najjar</surname><given-names>A</given-names></name><name><surname>Devinsky</surname><given-names>O</given-names></name></person-group>
<article-title>Neuroinflammation and psychiatric illness</article-title>
<source/>J Neuroinflammation
<year>2013</year>
<volume>10</volume>
<fpage>43</fpage>
<pub-id pub-id-type="pmid">23547920</pub-id></element-citation>
</ref>
<ref id="B21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Linden</surname><given-names>AM</given-names></name><name><surname>Greene</surname><given-names>SJ</given-names></name><name><surname>Bergeron</surname><given-names>M</given-names></name><name><surname>Schoepp</surname><given-names>DD</given-names></name></person-group>
<article-title>Anxiolytic activity of the MGLU2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions</article-title>
<source/>Neuropsychopharmacology
<year>2004</year>
<volume>29</volume>
<fpage>502</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="pmid">14694349</pub-id></element-citation>
</ref>
<ref id="B22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Swanson</surname><given-names>CJ</given-names></name><name><surname>Bures</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>MP</given-names></name><name><surname>Linden</surname><given-names>AM</given-names></name><name><surname>Monn</surname><given-names>JA</given-names></name><name><surname>Schoepp</surname><given-names>DD</given-names></name></person-group>
<article-title>Metabotropic glutamate receptors as novel targets for anxiety and stress disorders</article-title>
<source/>Nat Rev Drug Discov
<year>2005</year>
<volume>4</volume>
<fpage>131</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="pmid">15665858</pub-id></element-citation>
</ref>
<ref id="B23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schoepp</surname><given-names>DD</given-names></name></person-group>
<article-title>Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system</article-title>
<source/>J Pharmacol Exp Ther
<year>2001</year>
<volume>299</volume>
<fpage>12</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="pmid">11561058</pub-id></element-citation>
</ref>
<ref id="B24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hovatta</surname><given-names>I</given-names></name><name><surname>Tennant</surname><given-names>RS</given-names></name><name><surname>Helton</surname><given-names>R</given-names></name><name><surname>Marr</surname><given-names>RA</given-names></name><name><surname>Singer</surname><given-names>O</given-names></name><name><surname>Redwine</surname><given-names>JM</given-names></name><etal></etal></person-group>
<article-title>Glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice</article-title>
<source/>Nature
<year>2005</year>
<volume>438</volume>
<fpage>662</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">16244648</pub-id></element-citation>
</ref>
<ref id="B25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Landgraf</surname><given-names>R</given-names></name><name><surname>Kessler</surname><given-names>MS</given-names></name><name><surname>Bunck</surname><given-names>M</given-names></name><name><surname>Murgatroyd</surname><given-names>C</given-names></name><name><surname>Spengler</surname><given-names>D</given-names></name><name><surname>Zimbelmann</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Candidate genes of anxiety-related behavior in HAB/LAB rats and mice: focus on vasopressin and glyoxalase-I</article-title>
<source/>Neurosci Biobehav Rev
<year>2007</year>
<volume>31</volume>
<fpage>89</fpage>
<lpage>102</lpage>
<pub-id pub-id-type="pmid">16934871</pub-id></element-citation>
</ref>
<ref id="B26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bouayed</surname><given-names>J</given-names></name><name><surname>Rammal</surname><given-names>H</given-names></name><name><surname>Younos</surname><given-names>C</given-names></name><name><surname>Soulimani</surname><given-names>R</given-names></name></person-group>
<article-title>Positive correlation between peripheral blood granulocyte oxidative status and level of anxiety in mice</article-title>
<source/>Eur J Pharmacol
<year>2007</year>
<volume>564</volume>
<fpage>146</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">17395178</pub-id></element-citation>
</ref>
<ref id="B27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>YJ</given-names></name><name><surname>Wang</surname><given-names>YJ</given-names></name><name><surname>Huang</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name></person-group>
<article-title>Oxidative damage and HSP70 expression in masseter muscle induced by psychological stress in rats</article-title>
<source/>Physiol Behav
<year>2011</year>
<volume>104</volume>
<fpage>365</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="pmid">21515294</pub-id></element-citation>
</ref>
<ref id="B28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Noschang</surname><given-names>CG</given-names></name><name><surname>Pettenuzzo</surname><given-names>LF</given-names></name><name><surname>von Pozzer Toigo</surname><given-names>E</given-names></name><name><surname>Andreazza</surname><given-names>AC</given-names></name><name><surname>Krolow</surname><given-names>R</given-names></name><name><surname>Fachin</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Sex-specific differences on caffeine consumption and chronic stress-induced anxiety-like behavior and DNA breaks in the hippocampus</article-title>
<source/>Pharmacol Biochem Behav
<year>2009</year>
<volume>94</volume>
<fpage>63</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">19635494</pub-id></element-citation>
</ref>
<ref id="B29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Oliveira</surname><given-names>MR</given-names></name><name><surname>Silvestrin</surname><given-names>RB</given-names></name><name><surname>Mello E Souza</surname><given-names>T</given-names></name><name><surname>Moreira</surname><given-names>JC</given-names></name></person-group>
<article-title>Oxidative stress in the hippocampus, anxiety-like behavior and decreased locomotory and exploratory activity of adult rats: effects of sub acute vitamin A supplementation at therapeutic doses</article-title>
<source/>Neurotoxicology
<year>2007</year>
<volume>28</volume>
<fpage>1191</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">17727954</pub-id></element-citation>
</ref>
<ref id="B30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Salim</surname><given-names>S</given-names></name><name><surname>Sarraj</surname><given-names>N</given-names></name><name><surname>Taneja</surname><given-names>M</given-names></name><name><surname>Saha</surname><given-names>K</given-names></name><name><surname>Tejada-Simon</surname><given-names>MV</given-names></name><name><surname>Chugh</surname><given-names>G</given-names></name></person-group>
<article-title>Moderate treadmill exercise prevents oxidative stress-induced anxiety-like behavior in rats</article-title>
<source/>Behav Brain Res
<year>2010</year>
<volume>208</volume>
<fpage>545</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">20064565</pub-id></element-citation>
</ref>
<ref id="B31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Salim</surname><given-names>S</given-names></name><name><surname>Asghar</surname><given-names>M</given-names></name><name><surname>Chugh</surname><given-names>G</given-names></name><name><surname>Taneja</surname><given-names>M</given-names></name><name><surname>Xia</surname><given-names>Z</given-names></name><name><surname>Saha</surname><given-names>K</given-names></name></person-group>
<article-title>Oxidative stress: a potential recipe for anxiety, hypertension and insulin resistance</article-title>
<source/>Brain Res
<year>2010</year>
<volume>1359</volume>
<fpage>178</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="pmid">20816762</pub-id></element-citation>
</ref>
<ref id="B32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bulut</surname><given-names>M</given-names></name><name><surname>Selek</surname><given-names>S</given-names></name><name><surname>Bez</surname><given-names>Y</given-names></name><name><surname>Karababa</surname><given-names>IF</given-names></name><name><surname>Kaya</surname><given-names>MC</given-names></name><name><surname>Gunes</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Reduced PON1 enzymatic activity and increased lipid hydroperoxide levels that point out oxidative stress in generalized anxiety disorder</article-title>
<source/>J Affect Disord
<year>2013</year>
<volume>150</volume>
<fpage>829</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="pmid">23706841</pub-id></element-citation>
</ref>
<ref id="B33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kaya</surname><given-names>MC</given-names></name><name><surname>Bez</surname><given-names>Y</given-names></name><name><surname>Karababa</surname><given-names>IF</given-names></name><name><surname>Emhan</surname><given-names>A</given-names></name><name><surname>Aksoy</surname><given-names>N</given-names></name><name><surname>Bulut</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Decreased serum sulphydryl levels as a sign of increased oxidative stress in generalized anxiety disorder</article-title>
<source/>Psychiatry Investig
<year>2013</year>
<volume>10</volume>
<fpage>281</fpage>
<lpage>5</lpage>
</element-citation>
</ref>
<ref id="B34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Emhan</surname><given-names>A</given-names></name><name><surname>Selek</surname><given-names>S</given-names></name><name><surname>Bayazıt</surname><given-names>H</given-names></name><name><surname>Fatih Karababa</surname><given-names>İ</given-names></name><name><surname>Katı</surname><given-names>M</given-names></name><name><surname>Aksoy</surname><given-names>N</given-names></name></person-group>
<article-title>Evaluation of oxidative and antioxidative parameters in generalized anxiety disorder</article-title>
<source/>Psychiatry Res
<year>2015</year>
<volume>230</volume>
<fpage>806</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="pmid">26564548</pub-id></element-citation>
</ref>
<ref id="B35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kuloglu</surname><given-names>M</given-names></name><name><surname>Atmaca</surname><given-names>M</given-names></name><name><surname>Tezcan</surname><given-names>E</given-names></name><name><surname>Gecici</surname><given-names>O</given-names></name><name><surname>Tunckol</surname><given-names>H</given-names></name><name><surname>Ustundag</surname><given-names>B</given-names></name></person-group>
<article-title>Antioxidant enzyme activities and malondialdehyde levels in patients with obsessive-compulsive disorder</article-title>
<source/>Neuropsychobiology
<year>2002</year>
<volume>46</volume>
<fpage>27</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="pmid">12207144</pub-id></element-citation>
</ref>
<ref id="B36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ersan</surname><given-names>S</given-names></name><name><surname>Bakir</surname><given-names>S</given-names></name><name><surname>Erdal Ersan</surname><given-names>E</given-names></name><name><surname>Dogan</surname><given-names>O</given-names></name></person-group>
<article-title>Examination of free radical metabolism and antioxidant defence system elements in patients with obsessive-compulsive disorder</article-title>
<source/>Prog Neuropsychopharmacol Biol Psychiatry
<year>2006</year>
<volume>30</volume>
<fpage>1039</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="pmid">16682105</pub-id></element-citation>
</ref>
<ref id="B37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chakraborty</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>OP</given-names></name><name><surname>Dasgupta</surname><given-names>A</given-names></name><name><surname>Mandal</surname><given-names>N</given-names></name><name><surname>Nath Das</surname><given-names>H</given-names></name></person-group>
<article-title>Correlation between lipid peroxidation-induced TBARS level and disease severity in obsessive-compulsive disorder</article-title>
<source/>Prog Neuropsychopharmacol Biol Psychiatry
<year>2009</year>
<volume>33</volume>
<fpage>363</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">19272303</pub-id></element-citation>
</ref>
<ref id="B38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Behl</surname><given-names>A</given-names></name><name><surname>Swami</surname><given-names>G</given-names></name><name><surname>Sircar</surname><given-names>SS</given-names></name><name><surname>Bhatia</surname><given-names>MS</given-names></name><name><surname>Banerjee</surname><given-names>BD</given-names></name></person-group>
<article-title>Relationship of possible stress-related biochemical markers to oxidative/antioxidative status in obsessive-compulsive disorder</article-title>
<source/>Neuropsychobiology
<year>2010</year>
<volume>61</volume>
<fpage>210</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="pmid">20389131</pub-id></element-citation>
</ref>
<ref id="B39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kandemir</surname><given-names>H</given-names></name><name><surname>Abuhandan</surname><given-names>M</given-names></name><name><surname>Aksoy</surname><given-names>N</given-names></name><name><surname>Savik</surname><given-names>E</given-names></name><name><surname>Kaya</surname><given-names>C</given-names></name></person-group>
<article-title>Oxidative imbalance in child and adolescent patients with obsessive compulsive disorder</article-title>
<source/>J Psychiatr Res
<year>2013</year>
<volume>47</volume>
<fpage>1831</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="pmid">24011862</pub-id></element-citation>
</ref>
<ref id="B40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kuloglu</surname><given-names>M</given-names></name><name><surname>Atmaca</surname><given-names>M</given-names></name><name><surname>Tezcan</surname><given-names>E</given-names></name><name><surname>Ustundag</surname><given-names>B</given-names></name><name><surname>Bulut</surname><given-names>S</given-names></name></person-group>
<article-title>Antioxidant enzyme and malondialdehyde levels in patients with panic disorder</article-title>
<source/>Neuropsychobiology
<year>2002</year>
<volume>46</volume>
<fpage>186</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">12566935</pub-id></element-citation>
</ref>
<ref id="B41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Atmaca</surname><given-names>M</given-names></name><name><surname>Tezcan</surname><given-names>E</given-names></name><name><surname>Kuloglu</surname><given-names>M</given-names></name><name><surname>Ustundag</surname><given-names>B</given-names></name><name><surname>Tunckol</surname><given-names>H</given-names></name></person-group>
<article-title>Antioxidant enzyme and malondialdehyde values in social phobia before and after citalopram treatment</article-title>
<source/>Eur Arch Psychiatry Clin Neurosci
<year>2004</year>
<volume>254</volume>
<fpage>231</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">15309392</pub-id></element-citation>
</ref>
<ref id="B42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Atmaca</surname><given-names>M</given-names></name><name><surname>Kuloglu</surname><given-names>M</given-names></name><name><surname>Tezcan</surname><given-names>E</given-names></name><name><surname>Ustundag</surname><given-names>B</given-names></name></person-group>
<article-title>Antioxidant enzyme and malondialdehyde levels in patients with social phobia</article-title>
<source/>Psychiatry Res
<year>2008</year>
<volume>159</volume>
<fpage>95</fpage>
<lpage>100</lpage>
<pub-id pub-id-type="pmid">18339429</pub-id></element-citation>
</ref>
<ref id="B43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arranz</surname><given-names>L</given-names></name><name><surname>Guayerbas</surname><given-names>N</given-names></name><name><surname>De la Fuente</surname><given-names>M</given-names></name></person-group>
<article-title>Impairment of several immune functions in anxious women</article-title>
<source/>J Psychosom Res
<year>2007</year>
<volume>62</volume>
<fpage>1</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">17188114</pub-id></element-citation>
</ref>
<ref id="B44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Salim</surname><given-names>S</given-names></name><name><surname>Chugh</surname><given-names>G</given-names></name><name><surname>Asghar</surname><given-names>M</given-names></name></person-group>
<article-title>Inflammation in anxiety</article-title>
<source/>Adv Protein Chem Struct Biol
<year>2012</year>
<volume>88</volume>
<fpage>1</fpage>
<lpage>25</lpage>
<pub-id pub-id-type="pmid">22814704</pub-id></element-citation>
</ref>
<ref id="B45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miller</surname><given-names>AH</given-names></name><name><surname>Haroon</surname><given-names>E</given-names></name><name><surname>Raison</surname><given-names>CL</given-names></name><name><surname>Felger</surname><given-names>JC</given-names></name></person-group>
<article-title>Cytokine targets in the brain: impact on neurotransmitters and neurocircuits</article-title>
<source/>Depress Anxiety
<year>2013</year>
<volume>30</volume>
<fpage>297</fpage>
<lpage>306</lpage>
<pub-id pub-id-type="pmid">23468190</pub-id></element-citation>
</ref>
<ref id="B46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sakić</surname><given-names>B</given-names></name><name><surname>Szechtman</surname><given-names>H</given-names></name><name><surname>Talangbayan</surname><given-names>H</given-names></name><name><surname>Denburg</surname><given-names>SD</given-names></name><name><surname>Carbotte</surname><given-names>RM</given-names></name><name><surname>Denburg</surname><given-names>JA</given-names></name></person-group>
<article-title>Disturbed emotionality in autoimmune MRL-lpr mice</article-title>
<source/>Physiol Behav
<year>1994</year>
<volume>56</volume>
<fpage>609</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="pmid">7972416</pub-id></element-citation>
</ref>
<ref id="B47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schrott</surname><given-names>LM</given-names></name><name><surname>Crnic</surname><given-names>LS</given-names></name></person-group>
<article-title>Increased anxiety behaviors in autoimmune mice</article-title>
<source/>Behav Neurosci
<year>1996</year>
<volume>110</volume>
<fpage>492</fpage>
<lpage>502</lpage>
<pub-id pub-id-type="pmid">8888995</pub-id></element-citation>
</ref>
<ref id="B48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Connor</surname><given-names>TJ</given-names></name><name><surname>Leonard</surname><given-names>BE</given-names></name></person-group>
<article-title>Depression, stress and immunological activation: the role of cytokines in depressive disorders</article-title>
<source/>Life Sci
<year>1998</year>
<volume>62</volume>
<fpage>583</fpage>
<lpage>606</lpage>
<pub-id pub-id-type="pmid">9472719</pub-id></element-citation>
</ref>
<ref id="B49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fiore</surname><given-names>M</given-names></name><name><surname>Alleva</surname><given-names>E</given-names></name><name><surname>Probert</surname><given-names>L</given-names></name><name><surname>Kollias</surname><given-names>G</given-names></name><name><surname>Angelucci</surname><given-names>F</given-names></name><name><surname>Aloe</surname><given-names>L</given-names></name></person-group>
<article-title>Exploratory and displacement behavior in transgenic mice expressing high levels of brain TNF-alpha</article-title>
<source/>Physiol Behav
<year>1998</year>
<volume>63</volume>
<fpage>571</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">9523900</pub-id></element-citation>
</ref>
<ref id="B50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reichenberg</surname><given-names>A</given-names></name><name><surname>Yirmiya</surname><given-names>R</given-names></name><name><surname>Schuld</surname><given-names>A</given-names></name><name><surname>Kraus</surname><given-names>T</given-names></name><name><surname>Haack</surname><given-names>M</given-names></name><name><surname>Morag</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Cytokine-associated emotional and cognitive disturbances in humans</article-title>
<source/>Arch Gen Psychiatry
<year>2001</year>
<volume>58</volume>
<fpage>445</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">11343523</pub-id></element-citation>
</ref>
<ref id="B51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maes</surname><given-names>M</given-names></name><name><surname>Song</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>A</given-names></name><name><surname>De Jongh</surname><given-names>R</given-names></name><name><surname>Van Gastel</surname><given-names>A</given-names></name><name><surname>Kenis</surname><given-names>G</given-names></name><etal></etal></person-group>
<article-title>The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety</article-title>
<source/>Cytokine
<year>1998</year>
<volume>10</volume>
<fpage>313</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">9617578</pub-id></element-citation>
</ref>
<ref id="B52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pitsavos</surname><given-names>C</given-names></name><name><surname>Panagiotakos</surname><given-names>DB</given-names></name><name><surname>Papageorgiou</surname><given-names>C</given-names></name><name><surname>Tsetsekou</surname><given-names>E</given-names></name><name><surname>Soldatos</surname><given-names>C</given-names></name><name><surname>Stefanadis</surname><given-names>C</given-names></name></person-group>
<article-title>Anxiety in relation to inflammation and coagulation markers, among healthy adults: the ATTICA study</article-title>
<source/>Atherosclerosis
<year>2006</year>
<volume>185</volume>
<fpage>320</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">16005881</pub-id></element-citation>
</ref>
<ref id="B53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Millan</surname><given-names>MJ</given-names></name><name><surname>Gobert</surname><given-names>A</given-names></name><name><surname>Lejeune</surname><given-names>F</given-names></name><name><surname>Dekeyne</surname><given-names>A</given-names></name><name><surname>Newman-Tancredi</surname><given-names>A</given-names></name><name><surname>Pasteau</surname><given-names>V</given-names></name><etal></etal></person-group>
<article-title>The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways</article-title>
<source/>J Pharmacol Exp Ther
<year>2003</year>
<volume>306</volume>
<fpage>954</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="pmid">12750432</pub-id></element-citation>
</ref>
<ref id="B54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>San</surname><given-names>L</given-names></name><name><surname>Arranz</surname><given-names>B</given-names></name></person-group>
<article-title>Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system</article-title>
<source/>Eur Psychiatry
<year>2008</year>
<volume>23</volume>
<fpage>396</fpage>
<lpage>402</lpage>
<pub-id pub-id-type="pmid">18583104</pub-id></element-citation>
</ref>
<ref id="B55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Racagni</surname><given-names>G</given-names></name><name><surname>Riva</surname><given-names>MA</given-names></name><name><surname>Molteni</surname><given-names>R</given-names></name><name><surname>Musazzi</surname><given-names>L</given-names></name><name><surname>Calabrese</surname><given-names>F</given-names></name><name><surname>Popoli</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors</article-title>
<source/>World J Biol Psychiatry
<year>2011</year>
<volume>12</volume>
<fpage>574</fpage>
<lpage>87</lpage>
<pub-id pub-id-type="pmid">21999473</pub-id></element-citation>
</ref>
<ref id="B56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reagan</surname><given-names>LP</given-names></name><name><surname>Reznikov</surname><given-names>LR</given-names></name><name><surname>Evans</surname><given-names>AN</given-names></name><name><surname>Gabriel</surname><given-names>C</given-names></name><name><surname>Mocaër</surname><given-names>E</given-names></name><name><surname>Fadel</surname><given-names>JR</given-names></name></person-group>
<article-title>The antidepressant agomelatine inhibits stress-mediated changes in amino acid efflux in the rat hippocampus and amygdala</article-title>
<source/>Brain Res
<year>2012</year>
<volume>1466</volume>
<fpage>91</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">22647752</pub-id></element-citation>
</ref>
<ref id="B57">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tardito</surname><given-names>D</given-names></name><name><surname>Milanese</surname><given-names>M</given-names></name><name><surname>Bonifacino</surname><given-names>T</given-names></name><name><surname>Musazzi</surname><given-names>L</given-names></name><name><surname>Grilli</surname><given-names>M</given-names></name><name><surname>Mallei</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Blockade of stress-induced increase of glutamate release in the rat prefrontal/frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways</article-title>
<source/>BMC Neurosci
<year>2010</year>
<volume>11</volume>
<fpage>68</fpage>
<pub-id pub-id-type="pmid">20525261</pub-id></element-citation>
</ref>
<ref id="B58">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morley-Fletcher</surname><given-names>S</given-names></name><name><surname>Mairesse</surname><given-names>J</given-names></name><name><surname>Soumier</surname><given-names>A</given-names></name><name><surname>Banasr</surname><given-names>M</given-names></name><name><surname>Fagioli</surname><given-names>F</given-names></name><name><surname>Gabriel</surname><given-names>C</given-names></name><etal></etal></person-group>
<article-title>Chronic agomelatine treatment corrects behavioral, cellular, and biochemical abnormalities induced by prenatal stress in rats</article-title>
<source/>Psychopharmacology (Berl)
<year>2011</year>
<volume>217</volume>
<fpage>301</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="pmid">21503609</pub-id></element-citation>
</ref>
<ref id="B59">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aguiar</surname><given-names>CC</given-names></name><name><surname>Almeida</surname><given-names>AB</given-names></name><name><surname>Araújo</surname><given-names>PV</given-names></name><name><surname>Vasconcelos</surname><given-names>GS</given-names></name><name><surname>Chaves</surname><given-names>EM</given-names></name><name><surname>do Vale</surname><given-names>OC</given-names></name><etal></etal></person-group>
<article-title>Effects of agomelatine on oxidative stress in the brain of mice after chemically induced seizures</article-title>
<source/>Cell Mol Neurobiol
<year>2013</year>
<volume>33</volume>
<fpage>825</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="pmid">23801192</pub-id></element-citation>
</ref>
<ref id="B60">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Akpinar</surname><given-names>A</given-names></name><name><surname>Uğuz</surname><given-names>AC</given-names></name><name><surname>Nazıroğlu</surname><given-names>M</given-names></name></person-group>
<article-title>Agomelatine and duloxetine synergistically modulates apoptotic pathway by inhibiting oxidative stress triggered intracellular calcium entry in neuronal PC12 cells: role of TRPM2 and voltage-gated calcium channels</article-title>
<source/>J Membr Biol
<year>2014</year>
<volume>247</volume>
<fpage>451</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">24682240</pub-id></element-citation>
</ref>
<ref id="B61">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Molteni</surname><given-names>R</given-names></name><name><surname>Macchi</surname><given-names>F</given-names></name><name><surname>Zecchillo</surname><given-names>C</given-names></name><name><surname>Dell’agli</surname><given-names>M</given-names></name><name><surname>Colombo</surname><given-names>E</given-names></name><name><surname>Calabrese</surname><given-names>F</given-names></name><etal></etal></person-group>
<article-title>Modulation of the inflammatory response in rats chronically treated with the antidepressant agomelatine</article-title>
<source/>Eur Neuropsychopharmacol
<year>2013</year>
<volume>23</volume>
<fpage>1645</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="pmid">23622958</pub-id></element-citation>
</ref>
<ref id="B62">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hanisch</surname><given-names>UK</given-names></name><name><surname>Kettenmann</surname><given-names>H</given-names></name></person-group>
<article-title>Microglia: active sensor and versatile effector cells in the normal and pathologic brain</article-title>
<source/>Nat Neurosci
<year>2007</year>
<volume>10</volume>
<fpage>1387</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="pmid">17965659</pub-id></element-citation>
</ref>
<ref id="B63">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Bodinat</surname><given-names>C</given-names></name><name><surname>Guardiola-Lemaitre</surname><given-names>B</given-names></name><name><surname>Mocaër</surname><given-names>E</given-names></name><name><surname>Renard</surname><given-names>P</given-names></name><name><surname>Muñoz</surname><given-names>C</given-names></name><name><surname>Millan</surname><given-names>MJ</given-names></name></person-group>
<article-title>Agomelatine, the first melatonergic antidepressant: discovery, characterization and development</article-title>
<source/>Nat Rev Drug Discov
<year>2010</year>
<volume>9</volume>
<fpage>628</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="pmid">20577266</pub-id></element-citation>
</ref>
<ref id="B64">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Loiseau</surname><given-names>F</given-names></name><name><surname>Le Bihan</surname><given-names>C</given-names></name><name><surname>Hamon</surname><given-names>M</given-names></name><name><surname>Thiébot</surname><given-names>MH</given-names></name></person-group>
<article-title>Effects of melatonin and agomelatine in anxiety-related procedures in rats: interaction with diazepam</article-title>
<source/>Eur Neuropsychopharmacol
<year>2006</year>
<volume>16</volume>
<fpage>417</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="pmid">16376525</pub-id></element-citation>
</ref>
<ref id="B65">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Millan</surname><given-names>MJ</given-names></name><name><surname>Brocco</surname><given-names>M</given-names></name><name><surname>Gobert</surname><given-names>A</given-names></name><name><surname>Dekeyne</surname><given-names>A</given-names></name></person-group>
<article-title>Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade</article-title>
<source/>Psychopharmacology (Berl)
<year>2005</year>
<volume>177</volume>
<fpage>448</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="pmid">15289999</pub-id></element-citation>
</ref>
<ref id="B66">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Papp</surname><given-names>M</given-names></name><name><surname>Litwa</surname><given-names>E</given-names></name><name><surname>Gruca</surname><given-names>P</given-names></name><name><surname>Mocaër</surname><given-names>E</given-names></name></person-group>
<article-title>Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety</article-title>
<source/>Behav Pharmacol
<year>2006</year>
<volume>17</volume>
<fpage>9</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="pmid">16377959</pub-id></element-citation>
</ref>
<ref id="B67">
<label>67</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Egashira</surname><given-names>N</given-names></name><name><surname>Shirakawa</surname><given-names>A</given-names></name><name><surname>Abe</surname><given-names>M</given-names></name><name><surname>Niki</surname><given-names>T</given-names></name><name><surname>Mishima</surname><given-names>K</given-names></name><name><surname>Iwasaki</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>N-acetyl-L-cysteine inhibits marble-burying behavior in mice</article-title>
<source/>J Pharmacol Sci
<year>2012</year>
<volume>119</volume>
<fpage>97</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="pmid">22510519</pub-id></element-citation>
</ref>
<ref id="B68">
<label>68</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>YW</given-names></name><name><surname>Lin</surname><given-names>HC</given-names></name><name><surname>Ng</surname><given-names>MC</given-names></name><name><surname>Hsiao</surname><given-names>YH</given-names></name><name><surname>Wang</surname><given-names>CC</given-names></name><name><surname>Gean</surname><given-names>PW</given-names></name><etal></etal></person-group>
<article-title>Activation of mGluR2/3 underlies the effects of N-acetylcystein on amygdala-associated autism-like phenotypes in a valproate-induced rat model of autism</article-title>
<source/>Front Behav Neurosci
<year>2014</year>
<volume>8</volume>
<fpage>219</fpage>
<pub-id pub-id-type="pmid">24987341</pub-id></element-citation>
</ref>
<ref id="B69">
<label>69</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pilz</surname><given-names>LK</given-names></name><name><surname>Trojan</surname><given-names>Y</given-names></name><name><surname>Quiles</surname><given-names>CL</given-names></name><name><surname>Benvenutti</surname><given-names>R</given-names></name><name><surname>Melo</surname><given-names>G</given-names></name><name><surname>Levandovski</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>Effects of N-acetylcysteine and imipramine in a model of acute rhythm disruption in BALB/c mice</article-title>
<source/>Chronobiol Int
<year>2015</year>
<volume>32</volume>
<fpage>248</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="pmid">25286136</pub-id></element-citation>
</ref>
<ref id="B70">
<label>70</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mocelin</surname><given-names>R</given-names></name><name><surname>Herrmann</surname><given-names>AP</given-names></name><name><surname>Marcon</surname><given-names>M</given-names></name><name><surname>Rambo</surname><given-names>CL</given-names></name><name><surname>Rohden</surname><given-names>A</given-names></name><name><surname>Bevilaqua</surname><given-names>F</given-names></name><etal></etal></person-group>
<article-title>N-acetylcysteine prevents stress-induced anxiety behavior in zebrafish</article-title>
<source/>Pharmacol Biochem Behav
<year>2015</year>
<volume>139</volume>
<fpage>121</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">26261019</pub-id></element-citation>
</ref>
<ref id="B71">
<label>71</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Santos</surname><given-names>P</given-names></name><name><surname>Herrmann</surname><given-names>AP</given-names></name><name><surname>Benvenutti</surname><given-names>R</given-names></name><name><surname>Noetzold</surname><given-names>G</given-names></name><name><surname>Giongo</surname><given-names>F</given-names></name><name><surname>Gama</surname><given-names>CS</given-names></name><etal></etal></person-group>
<article-title>Anxiolytic properties of N-acetylcysteine in mice</article-title>
<source/>Behav Brain Res
<year>2017</year>
<volume>317</volume>
<fpage>461</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">27725170</pub-id></element-citation>
</ref>
<ref id="B72">
<label>72</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carrié</surname><given-names>I</given-names></name><name><surname>Smirnova</surname><given-names>M</given-names></name><name><surname>Clément</surname><given-names>M</given-names></name><name><surname>De</surname><given-names>JD</given-names></name><name><surname>Francès</surname><given-names>H</given-names></name><name><surname>Bourre</surname><given-names>JM</given-names></name></person-group>
<article-title>Docosahexaenoic acid-rich phospholipid supplementation: effect on behavior, learning ability, and retinal function in control and n-3 polyunsaturated fatty acid deficient old mice</article-title>
<source/>Nutr Neurosci
<year>2002</year>
<volume>5</volume>
<fpage>43</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">11929197</pub-id></element-citation>
</ref>
<ref id="B73">
<label>73</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Song</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Leonard</surname><given-names>BE</given-names></name><name><surname>Horrobin</surname><given-names>DF</given-names></name></person-group>
<article-title>Effects of dietary n-3 or n-6 fatty acids on interleukin-1beta-induced anxiety, stress, and inflammatory responses in rats</article-title>
<source/>J Lipid Res
<year>2003</year>
<volume>44</volume>
<fpage>1984</fpage>
<lpage>91</lpage>
<pub-id pub-id-type="pmid">12837849</pub-id></element-citation>
</ref>
<ref id="B74">
<label>74</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Song</surname><given-names>C</given-names></name><name><surname>Leonard</surname><given-names>BE</given-names></name><name><surname>Horrobin</surname><given-names>DF</given-names></name></person-group>
<article-title>Dietary ethyl-eicosapentaenoic acid but not soybean oil reverses central interleukin-1-induced changes in behavior, corticosterone and immune response in rats</article-title>
<source/>Stress
<year>2004</year>
<volume>7</volume>
<fpage>43</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="pmid">15204032</pub-id></element-citation>
</ref>
<ref id="B75">
<label>75</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ferraz</surname><given-names>AC</given-names></name><name><surname>Delattre</surname><given-names>AM</given-names></name><name><surname>Almendra</surname><given-names>RG</given-names></name><name><surname>Sonagli</surname><given-names>M</given-names></name><name><surname>Borges</surname><given-names>C</given-names></name><name><surname>Araujo</surname><given-names>P</given-names></name><etal></etal></person-group>
<article-title>Chronic ω-3 fatty acids supplementation promotes beneficial effects on anxiety, cognitive and depressive-like behaviors in rats subjected to a restraint stress protocol</article-title>
<source/>Behav Brain Res
<year>2011</year>
<volume>219</volume>
<fpage>116</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="pmid">21192985</pub-id></element-citation>
</ref>
<ref id="B76">
<label>76</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vinot</surname><given-names>N</given-names></name><name><surname>Jouin</surname><given-names>M</given-names></name><name><surname>Lhomme-Duchadeuil</surname><given-names>A</given-names></name><name><surname>Guesnet</surname><given-names>P</given-names></name><name><surname>Alessandri</surname><given-names>JM</given-names></name><name><surname>Aujard</surname><given-names>F</given-names></name><etal></etal></person-group>
<article-title>Omega-3 fatty acids from fish oil lower anxiety, improve cognitive functions and reduce spontaneous locomotor activity in a non-human primate</article-title>
<source/>PloS One
<year>2011</year>
<volume>6</volume>
<fpage>e20491</fpage>
<pub-id pub-id-type="pmid">21666750</pub-id></element-citation>
</ref>
<ref id="B77">
<label>77</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pérez</surname><given-names>MÁ</given-names></name><name><surname>Terreros</surname><given-names>G</given-names></name><name><surname>Dagnino-Subiabre</surname><given-names>A</given-names></name></person-group>
<article-title>Long-term ω-3 fatty acid supplementation induces anti-stress effects and improves learning in rats</article-title>
<source/>Behav Brain Funct
<year>2013</year>
<volume>9</volume>
<fpage>25</fpage>
<pub-id pub-id-type="pmid">23768007</pub-id></element-citation>
</ref>
<ref id="B78">
<label>78</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jašarević</surname><given-names>E</given-names></name><name><surname>Hecht</surname><given-names>PM</given-names></name><name><surname>Fritsche</surname><given-names>KL</given-names></name><name><surname>Beversdorf</surname><given-names>DQ</given-names></name><name><surname>Geary</surname><given-names>DC</given-names></name></person-group>
<article-title>Dissociable effects of dorsal and ventral hippocampal DHA content on spatial learning and anxiety-like behavior</article-title>
<source/>Neurobiol Learn Mem
<year>2014</year>
<volume>116</volume>
<fpage>59</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="pmid">25180934</pub-id></element-citation>
</ref>
<ref id="B79">
<label>79</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pifferi</surname><given-names>F</given-names></name><name><surname>Dorieux</surname><given-names>O</given-names></name><name><surname>Castellano</surname><given-names>CA</given-names></name><name><surname>Croteau</surname><given-names>E</given-names></name><name><surname>Masson</surname><given-names>M</given-names></name><name><surname>Guillermier</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Long-chain n-3 PUFAs from fish oil enhance resting state brain glucose utilization and reduce anxiety in an adult nonhuman primate, the grey mouse lemur</article-title>
<source/>J Lipid Res
<year>2015</year>
<volume>56</volume>
<fpage>1511</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">26063461</pub-id></element-citation>
</ref>
<ref id="B80">
<label>80</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stein</surname><given-names>DJ</given-names></name><name><surname>Ahokas</surname><given-names>AA</given-names></name><name><surname>de Bodinat</surname><given-names>C</given-names></name></person-group>
<article-title>Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study</article-title>
<source/>J Clin Psychopharmacol
<year>2008</year>
<volume>28</volume>
<fpage>561</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">18794654</pub-id></element-citation>
</ref>
<ref id="B81">
<label>81</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stein</surname><given-names>DJ</given-names></name><name><surname>Ahokas</surname><given-names>A</given-names></name><name><surname>Albarran</surname><given-names>C</given-names></name><name><surname>Olivier</surname><given-names>V</given-names></name><name><surname>Allgulander</surname><given-names>C</given-names></name></person-group>
<article-title>Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study</article-title>
<source/>J Clin Psychiatry
<year>2012</year>
<volume>73</volume>
<fpage>1002</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">22901350</pub-id></element-citation>
</ref>
<ref id="B82">
<label>82</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stein</surname><given-names>DJ</given-names></name><name><surname>Ahokas</surname><given-names>A</given-names></name><name><surname>Márquez</surname><given-names>MS</given-names></name><name><surname>Höschl</surname><given-names>C</given-names></name><name><surname>Oh</surname><given-names>KS</given-names></name><name><surname>Jarema</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study</article-title>
<source/>J Clin Psychiatry
<year>2014</year>
<volume>75</volume>
<fpage>362</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">24569045</pub-id></element-citation>
</ref>
<ref id="B83">
<label>83</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stein</surname><given-names>DJ</given-names></name><name><surname>Ahokas</surname><given-names>A</given-names></name><name><surname>Jarema</surname><given-names>M</given-names></name><name><surname>Avedisova</surname><given-names>AS</given-names></name><name><surname>Vavrusova</surname><given-names>L</given-names></name><name><surname>Chaban</surname><given-names>O</given-names></name><etal></etal></person-group>
<article-title>Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: a 12-week, double-blind, placebo-controlled study</article-title>
<source/>Eur Neuropsychopharmacol
<year>2017</year>
<volume>27</volume>
<fpage>526</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="pmid">28298261</pub-id></element-citation>
</ref>
<ref id="B84">
<label>84</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Durieux</surname><given-names>AM</given-names></name><name><surname>Fernandes</surname><given-names>C</given-names></name><name><surname>Murphy</surname><given-names>D</given-names></name><name><surname>Labouesse</surname><given-names>MA</given-names></name><name><surname>Giovanoli</surname><given-names>S</given-names></name><name><surname>Meyer</surname><given-names>U</given-names></name><etal></etal></person-group>
<article-title>Targeting glia with N-acetylcysteine modulates brain glutamate and behaviors relevant to neurodevelopmental disorders in C57BL/6J mice</article-title>
<source/>Front Behav Neurosci
<year>2015</year>
<volume>9</volume>
<fpage>343</fpage>
<pub-id pub-id-type="pmid">26696857</pub-id></element-citation>
</ref>
<ref id="B85">
<label>85</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Afshar</surname><given-names>H</given-names></name><name><surname>Roohafza</surname><given-names>H</given-names></name><name><surname>Mohammad-Beigi</surname><given-names>H</given-names></name><name><surname>Haghighi</surname><given-names>M</given-names></name><name><surname>Jahangard</surname><given-names>L</given-names></name><name><surname>Shokouh</surname><given-names>P</given-names></name><etal></etal></person-group>
<article-title>N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial</article-title>
<source/>J Clin Psychopharmacol
<year>2012</year>
<volume>32</volume>
<fpage>797</fpage>
<lpage>803</lpage>
<pub-id pub-id-type="pmid">23131885</pub-id></element-citation>
</ref>
<ref id="B86">
<label>86</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ghanizadeh</surname><given-names>A</given-names></name><name><surname>Derakhshan</surname><given-names>N</given-names></name><name><surname>Berk</surname><given-names>M</given-names></name></person-group>
<article-title>N-acetylcysteine versus placebo for treating nail biting, a double blind randomized placebo controlled clinical trial</article-title>
<source/>Antiinflamm Antiallergy Agents Med Chem
<year>2013</year>
<volume>12</volume>
<fpage>223</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">23651231</pub-id></element-citation>
</ref>
<ref id="B87">
<label>87</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sarris</surname><given-names>J</given-names></name><name><surname>Oliver</surname><given-names>G</given-names></name><name><surname>Camfield</surname><given-names>DA</given-names></name><name><surname>Dean</surname><given-names>OM</given-names></name><name><surname>Dowling</surname><given-names>N</given-names></name><name><surname>Smith</surname><given-names>DJ</given-names></name><etal></etal></person-group>
<article-title>N-acetyl cysteine (nac) in the treatment of obsessive-compulsive disorder: a 16-week, double-blind, randomised, placebo-controlled study</article-title>
<source/>CNS Drugs
<year>2015</year>
<volume>29</volume>
<fpage>801</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">26374743</pub-id></element-citation>
</ref>
<ref id="B88">
<label>88</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Back</surname><given-names>SE</given-names></name><name><surname>McCauley</surname><given-names>JL</given-names></name><name><surname>Korte</surname><given-names>KJ</given-names></name><name><surname>Gros</surname><given-names>DF</given-names></name><name><surname>Leavitt</surname><given-names>V</given-names></name><name><surname>Gray</surname><given-names>KM</given-names></name><etal></etal></person-group>
<article-title>A double-blind, randomized, controlled pilot trial of N-acetylcysteine in veterans with posttraumatic stress disorder and substance use disorders</article-title>
<source/>J Clin Psychiatry
<year>2016</year>
<volume>77</volume>
<fpage>e1439</fpage>
<lpage>e46</lpage>
<pub-id pub-id-type="pmid">27736051</pub-id></element-citation>
</ref>
<ref id="B89">
<label>89</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grant</surname><given-names>JE</given-names></name><name><surname>Chamberlain</surname><given-names>SR</given-names></name><name><surname>Redden</surname><given-names>SA</given-names></name><name><surname>Leppink</surname><given-names>EW</given-names></name><name><surname>Odlaug</surname><given-names>BL</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name></person-group>
<article-title>N-acetylcysteine in the treatment of excoriation disorder: a randomized clinical trial</article-title>
<source/>JAMA Psychiatry
<year>2016</year>
<volume>73</volume>
<fpage>490</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">27007062</pub-id></element-citation>
</ref>
<ref id="B90">
<label>90</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Paydary</surname><given-names>K</given-names></name><name><surname>Akamaloo</surname><given-names>A</given-names></name><name><surname>Ahmadipour</surname><given-names>A</given-names></name><name><surname>Pishgar</surname><given-names>F</given-names></name><name><surname>Emamzadehfard</surname><given-names>S</given-names></name><name><surname>Akhondzadeh</surname><given-names>S</given-names></name></person-group>
<article-title>N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial</article-title>
<source/>J Clin Pharm Ther
<year>2016</year>
<volume>41</volume>
<fpage>214</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">26931055</pub-id></element-citation>
</ref>
<ref id="B91">
<label>91</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yehuda</surname><given-names>S</given-names></name><name><surname>Rabinovitz</surname><given-names>S</given-names></name><name><surname>Mostofsky</surname><given-names>DI</given-names></name></person-group>
<article-title>Mixture of essential fatty acids lowers test anxiety</article-title>
<source/>Nutr Neurosci
<year>2005</year>
<volume>8</volume>
<fpage>265</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">16491653</pub-id></element-citation>
</ref>
<ref id="B92">
<label>92</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Buydens-Branchey</surname><given-names>L</given-names></name><name><surname>Branchey</surname><given-names>M</given-names></name></person-group>
<article-title>n-3 polyunsaturated fatty acids decrease anxiety feelings in a population of substance abusers</article-title>
<source/>J Clin Psychopharmacol
<year>2006</year>
<volume>26</volume>
<fpage>661</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">17110827</pub-id></element-citation>
</ref>
<ref id="B93">
<label>93</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Buydens-Branchey</surname><given-names>L</given-names></name><name><surname>Branchey</surname><given-names>M</given-names></name><name><surname>Hibbeln</surname><given-names>JR</given-names></name></person-group>
<article-title>Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers</article-title>
<source/>Prog Neuropsychopharmacol Biol Psychiatry
<year>2008</year>
<volume>32</volume>
<fpage>568</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="pmid">18060675</pub-id></element-citation>
</ref>
<ref id="B94">
<label>94</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kiecolt-Glaser</surname><given-names>JK</given-names></name><name><surname>Belury</surname><given-names>MA</given-names></name><name><surname>Andridge</surname><given-names>R</given-names></name><name><surname>Malarkey</surname><given-names>WB</given-names></name><name><surname>Glaser</surname><given-names>R</given-names></name></person-group>
<article-title>Omega-3 supplementation lowers inflammation and anxiety in medical students: a randomized controlled trial</article-title>
<source/>Brain Behav Immun
<year>2011</year>
<volume>25</volume>
<fpage>1725</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="pmid">21784145</pub-id></element-citation>
</ref>
<ref id="B95">
<label>95</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barbadoro</surname><given-names>P</given-names></name><name><surname>Annino</surname><given-names>I</given-names></name><name><surname>Ponzio</surname><given-names>E</given-names></name><name><surname>Romanelli</surname><given-names>RM</given-names></name><name><surname>D’Errico</surname><given-names>MM</given-names></name><name><surname>Prospero</surname><given-names>E</given-names></name><etal></etal></person-group>
<article-title>Fish oil supplementation reduces cortisol basal levels and perceived stress: a randomized, placebo-controlled trial in abstinent alcoholics</article-title>
<source/>Mol Nutr Food Res
<year>2013</year>
<volume>57</volume>
<fpage>1110</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="pmid">23390041</pub-id></element-citation>
</ref>
<ref id="B96">
<label>96</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haberka</surname><given-names>M</given-names></name><name><surname>Mizia-Stec</surname><given-names>K</given-names></name><name><surname>Mizia</surname><given-names>M</given-names></name><name><surname>Gieszczyk</surname><given-names>K</given-names></name><name><surname>Chmiel</surname><given-names>A</given-names></name><name><surname>Sitnik-Warchulska</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>Effects of n-3 polyunsaturated fatty acids on depressive symptoms, anxiety and emotional state in patients with acute myocardial infarction</article-title>
<source/>Pharmacol Rep
<year>2013</year>
<volume>65</volume>
<fpage>59</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="pmid">23563024</pub-id></element-citation>
</ref>
<ref id="B97">
<label>97</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sohrabi</surname><given-names>N</given-names></name><name><surname>Kashanian</surname><given-names>M</given-names></name><name><surname>Ghafoori</surname><given-names>SS</given-names></name><name><surname>Malakouti</surname><given-names>SK</given-names></name></person-group>
<article-title>Evaluation of the effect of omega-3 fatty acids in the treatment of premenstrual syndrome: “a pilot trial.”</article-title>
<source/>Complement Ther Med
<year>2013</year>
<volume>21</volume>
<fpage>141</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">23642943</pub-id></element-citation>
</ref>
<ref id="B98">
<label>98</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matsumura</surname><given-names>K</given-names></name><name><surname>Noguchi</surname><given-names>H</given-names></name><name><surname>Nishi</surname><given-names>D</given-names></name><name><surname>Hamazaki</surname><given-names>K</given-names></name><name><surname>Hamazaki</surname><given-names>T</given-names></name><name><surname>Matsuoka</surname><given-names>YJ</given-names></name></person-group>
<article-title>Effects of omega-3 polyunsaturated fatty acids on psychophysiological symptoms of posttraumatic stress disorder in accident survivors: a randomized, double-blind, placebo-controlled trial</article-title>
<source/>J Affect Disord
<year>2017</year>
<volume>224</volume>
<fpage>27</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="pmid">27287561</pub-id></element-citation>
</ref>
<ref id="B99">
<label>99</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huijbregts</surname><given-names>KM</given-names></name><name><surname>Batelaan</surname><given-names>NM</given-names></name><name><surname>Schonenberg</surname><given-names>J</given-names></name><name><surname>Veen</surname><given-names>G</given-names></name><name><surname>van Balkom</surname><given-names>AJ</given-names></name></person-group>
<article-title>Agomelatine as a novel treatment option in panic disorder, results from an 8-week open-label trial</article-title>
<source/>J Clin Psychopharmacol
<year>2015</year>
<volume>35</volume>
<fpage>336</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">25856784</pub-id></element-citation>
</ref>
<ref id="B100">
<label>100</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lôo</surname><given-names>H</given-names></name><name><surname>Hale</surname><given-names>A</given-names></name><name><surname>D’haenen</surname><given-names>H</given-names></name></person-group>
<article-title>Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study</article-title>
<source/>Int Clin Psychopharmacol
<year>2002</year>
<volume>17</volume>
<fpage>239</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="pmid">12177586</pub-id></element-citation>
</ref>
<ref id="B101">
<label>101</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Olié</surname><given-names>JP</given-names></name><name><surname>Kasper</surname><given-names>S</given-names></name></person-group>
<article-title>Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder</article-title>
<source/>Int J Neuropsychopharmacol
<year>2007</year>
<volume>10</volume>
<fpage>661</fpage>
<lpage>73</lpage>
<pub-id pub-id-type="pmid">17477888</pub-id></element-citation>
</ref>
<ref id="B102">
<label>102</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>SH</given-names></name><name><surname>Emsley</surname><given-names>R</given-names></name></person-group>
<article-title>Placebo-controlled trial of agomelatine in the treatment of major depressive disorder</article-title>
<source/>Eur Neuropsychopharmacol
<year>2006</year>
<volume>16</volume>
<fpage>93</fpage>
<lpage>100</lpage>
<pub-id pub-id-type="pmid">16249073</pub-id></element-citation>
</ref>
<ref id="B103">
<label>103</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lemoine</surname><given-names>P</given-names></name><name><surname>Guilleminault</surname><given-names>C</given-names></name><name><surname>Alvarez</surname><given-names>E</given-names></name></person-group>
<article-title>Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine</article-title>
<source/>J Clin Psychiatry
<year>2007</year>
<volume>68</volume>
<fpage>1723</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="pmid">18052566</pub-id></element-citation>
</ref>
<ref id="B104">
<label>104</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hale</surname><given-names>A</given-names></name><name><surname>Corral</surname><given-names>RM</given-names></name><name><surname>Mencacci</surname><given-names>C</given-names></name><name><surname>Ruiz</surname><given-names>JS</given-names></name><name><surname>Severo</surname><given-names>CA</given-names></name><name><surname>Gentil</surname><given-names>V</given-names></name></person-group>
<article-title>Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study</article-title>
<source/>Int Clin Psychopharmacol
<year>2010</year>
<volume>25</volume>
<fpage>305</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="pmid">20856123</pub-id></element-citation>
</ref>
<ref id="B105">
<label>105</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kasper</surname><given-names>S</given-names></name><name><surname>Hajak</surname><given-names>G</given-names></name><name><surname>Wulff</surname><given-names>K</given-names></name><name><surname>Hoogendijk</surname><given-names>WJ</given-names></name><name><surname>Montejo</surname><given-names>AL</given-names></name><name><surname>Smeraldi</surname><given-names>E</given-names></name><etal></etal></person-group>
<article-title>Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline</article-title>
<source/>J Clin Psychiatry
<year>2010</year>
<volume>71</volume>
<fpage>109</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="pmid">20193645</pub-id></element-citation>
</ref>
<ref id="B106">
<label>106</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stein</surname><given-names>DJ</given-names></name><name><surname>Picarel-Blanchot</surname><given-names>F</given-names></name><name><surname>Kennedy</surname><given-names>SH</given-names></name></person-group>
<article-title>Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression</article-title>
<source/>Hum Psychopharmacol
<year>2013</year>
<volume>28</volume>
<fpage>151</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">23532747</pub-id></element-citation>
</ref>
<ref id="B107">
<label>107</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goodwin</surname><given-names>GM</given-names></name><name><surname>Emsley</surname><given-names>R</given-names></name><name><surname>Rembry</surname><given-names>S</given-names></name><name><surname>Rouillon</surname><given-names>F</given-names></name></person-group>
<person-group person-group-type="author"><collab>Agomelatine Study Group</collab></person-group>
<article-title>Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial</article-title>
<source/>J Clin Psychiatry
<year>2009</year>
<volume>70</volume>
<fpage>1128</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="pmid">19689920</pub-id></element-citation>
</ref>
<ref id="B108">
<label>108</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Berardis</surname><given-names>D</given-names></name><name><surname>Di Iorio</surname><given-names>G</given-names></name><name><surname>Acciavatti</surname><given-names>T</given-names></name><name><surname>Conti</surname><given-names>C</given-names></name><name><surname>Serroni</surname><given-names>N</given-names></name><name><surname>Olivieri</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine</article-title>
<source/>CNS Neurol Disord Drug Targets
<year>2011</year>
<volume>10</volume>
<fpage>119</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="pmid">20874703</pub-id></element-citation>
</ref>
<ref id="B109">
<label>109</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Green</surname><given-names>B</given-names></name></person-group>
<article-title>Focus on agomelatine</article-title>
<source/>Curr Med Res Opin
<year>2011</year>
<volume>27</volume>
<fpage>745</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">21271795</pub-id></element-citation>
</ref>
<ref id="B110">
<label>110</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dean</surname><given-names>O</given-names></name><name><surname>Giorlando</surname><given-names>F</given-names></name><name><surname>Berk</surname><given-names>M</given-names></name></person-group>
<article-title>N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action</article-title>
<source/>J Psychiatry Neurosci
<year>2011</year>
<volume>36</volume>
<fpage>78</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="pmid">21118657</pub-id></element-citation>
</ref>
<ref id="B111">
<label>111</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deepmala, Slattery</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>N</given-names></name><name><surname>Delhey</surname><given-names>L</given-names></name><name><surname>Berk</surname><given-names>M</given-names></name><name><surname>Dean</surname><given-names>O</given-names></name><etal></etal></person-group>
<article-title>Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review</article-title>
<source/>Neurosci Biobehav Rev
<year>2015</year>
<volume>55</volume>
<fpage>294</fpage>
<lpage>321</lpage>
<pub-id pub-id-type="pmid">25957927</pub-id></element-citation>
</ref>
<ref id="B112">
<label>112</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Palacio</surname><given-names>JR</given-names></name><name><surname>Markert</surname><given-names>UR</given-names></name><name><surname>Martínez</surname><given-names>P</given-names></name></person-group>
<article-title>Anti-inflammatory properties of N-acetylcysteine on lipopolysaccharide-activated macrophages</article-title>
<source/>Inflamm Res
<year>2011</year>
<volume>60</volume>
<fpage>695</fpage>
<lpage>704</lpage>
<pub-id pub-id-type="pmid">21424515</pub-id></element-citation>
</ref>
<ref id="B113">
<label>113</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Gallo</surname><given-names>DJ</given-names></name><name><surname>Baust</surname><given-names>JJ</given-names></name><name><surname>Watkins</surname><given-names>SK</given-names></name><name><surname>Delude</surname><given-names>RL</given-names></name><name><surname>Fink</surname><given-names>MP</given-names></name></person-group>
<article-title>Effect of hemorrhagic shock on gut barrier function and expression of stress-related genes in normal and gnotobiotic mice</article-title>
<source/>Am J Physiol Regul Integr Comp Physiol
<year>2002</year>
<volume>283</volume>
<fpage>R1263</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="pmid">12376421</pub-id></element-citation>
</ref>
<ref id="B114">
<label>114</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Berk</surname><given-names>M</given-names></name><name><surname>Malhi</surname><given-names>GS</given-names></name><name><surname>Gray</surname><given-names>LJ</given-names></name><name><surname>Dean</surname><given-names>OM</given-names></name></person-group>
<article-title>The promise of N-acetylcysteine in neuropsychiatry</article-title>
<source/>Trends Pharmacol Sci
<year>2013</year>
<volume>34</volume>
<fpage>167</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="pmid">23369637</pub-id></element-citation>
</ref>
<ref id="B115">
<label>115</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tsai</surname><given-names>GY</given-names></name><name><surname>Cui</surname><given-names>JZ</given-names></name><name><surname>Syed</surname><given-names>H</given-names></name><name><surname>Xia</surname><given-names>Z</given-names></name><name><surname>Ozerdem</surname><given-names>U</given-names></name><name><surname>McNeill</surname><given-names>JH</given-names></name><etal></etal></person-group>
<article-title>Effect of N-acetylcysteine on the early expression of inflammatory markers in the retina and plasma of diabetic rats</article-title>
<source/>Clin Exp Ophthalmol
<year>2009</year>
<volume>37</volume>
<fpage>223</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="pmid">19723131</pub-id></element-citation>
</ref>
<ref id="B116">
<label>116</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kigerl</surname><given-names>KA</given-names></name><name><surname>Ankeny</surname><given-names>DP</given-names></name><name><surname>Garg</surname><given-names>SK</given-names></name><name><surname>Wei</surname><given-names>P</given-names></name><name><surname>Guan</surname><given-names>Z</given-names></name><name><surname>Lai</surname><given-names>W</given-names></name><etal></etal></person-group>
<article-title>System xc- regulates microglia and macrophage glutamate excitotoxicity in vivo</article-title>
<source/>Exp Neurol
<year>2012</year>
<volume>233</volume>
<fpage>333</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="pmid">22079587</pub-id></element-citation>
</ref>
<ref id="B117">
<label>117</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Hang</surname><given-names>C</given-names></name></person-group>
<article-title>Inhibitory effect on cerebral inflammatory response following traumatic brain injury in rats: a potential neuroprotective mechanism of N-acetylcysteine</article-title>
<source/>Mediators Inflamm
<year>2008</year>
<volume>2008</volume>
<fpage>716458</fpage>
<pub-id pub-id-type="pmid">18483565</pub-id></element-citation>
</ref>
<ref id="B118">
<label>118</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jatana</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>I</given-names></name><name><surname>Singh</surname><given-names>AK</given-names></name><name><surname>Jenkins</surname><given-names>D</given-names></name></person-group>
<article-title>Combination of systemic hypothermia and N-acetylcysteine attenuates hypoxic-ischemic brain injury in neonatal rats</article-title>
<source/>Pediatr Res
<year>2006</year>
<volume>59</volume>
<fpage>684</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">16627882</pub-id></element-citation>
</ref>
<ref id="B119">
<label>119</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Sekhon</surname><given-names>B</given-names></name><name><surname>Jatana</surname><given-names>M</given-names></name><name><surname>Giri</surname><given-names>S</given-names></name><name><surname>Gilg</surname><given-names>AG</given-names></name><name><surname>Sekhon</surname><given-names>C</given-names></name><etal></etal></person-group>
<article-title>Administration of N-acetylcysteine after focal cerebral ischemia protects brain and reduces inflammation in a rat model of experimental stroke</article-title>
<source/>J Neurosci Res
<year>2004</year>
<volume>76</volume>
<fpage>519</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="pmid">15114624</pub-id></element-citation>
</ref>
<ref id="B120">
<label>120</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gatti</surname><given-names>S</given-names></name><name><surname>Faggioni</surname><given-names>R</given-names></name><name><surname>Echtenacher</surname><given-names>B</given-names></name><name><surname>Ghezzi</surname><given-names>P</given-names></name></person-group>
<article-title>Role of tumour necrosis factor and reactive oxygen intermediates in lipopolysaccharide-induced pulmonary oedema and lethality</article-title>
<source/>Clin Exp Immunol
<year>1993</year>
<volume>91</volume>
<fpage>456</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="pmid">8443968</pub-id></element-citation>
</ref>
<ref id="B121">
<label>121</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Victor</surname><given-names>VM</given-names></name><name><surname>Rocha</surname><given-names>M</given-names></name><name><surname>De la Fuente</surname><given-names>M</given-names></name></person-group>
<article-title>N-acetylcysteine protects mice from lethal endotoxemia by regulating the redox state of immune cells</article-title>
<source/>Free Radic Res
<year>2003</year>
<volume>37</volume>
<fpage>919</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="pmid">14669999</pub-id></element-citation>
</ref>
<ref id="B122">
<label>122</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Blackwell</surname><given-names>TS</given-names></name><name><surname>Blackwell</surname><given-names>TR</given-names></name><name><surname>Holden</surname><given-names>EP</given-names></name><name><surname>Christman</surname><given-names>BW</given-names></name><name><surname>Christman</surname><given-names>JW</given-names></name></person-group>
<article-title>In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation</article-title>
<source/>J Immunol
<year>1996</year>
<volume>157</volume>
<fpage>1630</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">8759749</pub-id></element-citation>
</ref>
<ref id="B123">
<label>123</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Csontos</surname><given-names>C</given-names></name><name><surname>Rezman</surname><given-names>B</given-names></name><name><surname>Foldi</surname><given-names>V</given-names></name><name><surname>Bogar</surname><given-names>L</given-names></name><name><surname>Drenkovics</surname><given-names>L</given-names></name><name><surname>Röth</surname><given-names>E</given-names></name><etal></etal></person-group>
<article-title>Effect of N-acetylcysteine treatment on oxidative stress and inflammation after severe burn</article-title>
<source/>Burns
<year>2012</year>
<volume>38</volume>
<fpage>428</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="pmid">21978796</pub-id></element-citation>
</ref>
<ref id="B124">
<label>124</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nascimento</surname><given-names>MM</given-names></name><name><surname>Suliman</surname><given-names>ME</given-names></name><name><surname>Silva</surname><given-names>M</given-names></name><name><surname>Chinaglia</surname><given-names>T</given-names></name><name><surname>Marchioro</surname><given-names>J</given-names></name><name><surname>Hayashi</surname><given-names>SY</given-names></name><etal></etal></person-group>
<article-title>Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo-controlled study</article-title>
<source/>Perit Dial Int
<year>2010</year>
<volume>30</volume>
<fpage>336</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="pmid">20190028</pub-id></element-citation>
</ref>
<ref id="B125">
<label>125</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mahmoud</surname><given-names>KM</given-names></name><name><surname>Ammar</surname><given-names>AS</given-names></name></person-group>
<article-title>Effect of N-acetylcysteine on cardiac injury and oxidative stress after abdominal aortic aneurysm repair: a randomized controlled trial</article-title>
<source/>Acta Anaesthesiol Scand
<year>2011</year>
<volume>55</volume>
<fpage>1015</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="pmid">22092168</pub-id></element-citation>
</ref>
<ref id="B126">
<label>126</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grant</surname><given-names>JE</given-names></name><name><surname>Odlaug</surname><given-names>BL</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name></person-group>
<article-title>N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study</article-title>
<source/>Arch Gen Psychiatry
<year>2009</year>
<volume>66</volume>
<fpage>756</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="pmid">19581567</pub-id></element-citation>
</ref>
<ref id="B127">
<label>127</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Odlaug</surname><given-names>BL</given-names></name><name><surname>Grant</surname><given-names>JE</given-names></name></person-group>
<article-title>N-acetyl cysteine in the treatment of grooming disorders</article-title>
<source/>J Clin Psychopharmacol
<year>2007</year>
<volume>27</volume>
<fpage>227</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">17414258</pub-id></element-citation>
</ref>
<ref id="B128">
<label>128</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rodrigues-Barata</surname><given-names>AR</given-names></name><name><surname>Tosti</surname><given-names>A</given-names></name><name><surname>Rodríguez-Pichardo</surname><given-names>A</given-names></name><name><surname>Camacho-Martínez</surname><given-names>F</given-names></name></person-group>
<article-title>N-acetylcysteine in the treatment of trichotillomania</article-title>
<source/>Int J Trichology
<year>2012</year>
<volume>4</volume>
<fpage>176</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">23180931</pub-id></element-citation>
</ref>
<ref id="B129">
<label>129</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Taylor</surname><given-names>M</given-names></name><name><surname>Bhagwandas</surname><given-names>K</given-names></name></person-group>
<article-title>N-acetylcysteine in trichotillomania: a panacea for compulsive skin disorders?</article-title>
<source/>Br J Dermatol
<year>2014</year>
<volume>171</volume>
<fpage>1253</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">24773206</pub-id></element-citation>
</ref>
<ref id="B130">
<label>130</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bloch</surname><given-names>MH</given-names></name><name><surname>Panza</surname><given-names>KE</given-names></name><name><surname>Grant</surname><given-names>JE</given-names></name><name><surname>Pittenger</surname><given-names>C</given-names></name><name><surname>Leckman</surname><given-names>JF</given-names></name></person-group>
<article-title>N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial</article-title>
<source/>J Am Acad Child Adolesc Psychiatry
<year>2013</year>
<volume>52</volume>
<fpage>231</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="pmid">23452680</pub-id></element-citation>
</ref>
<ref id="B131">
<label>131</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grant</surname><given-names>JE</given-names></name><name><surname>Odlaug</surname><given-names>BL</given-names></name><name><surname>Chamberlain</surname><given-names>SR</given-names></name><name><surname>Keuthen</surname><given-names>NJ</given-names></name><name><surname>Lochner</surname><given-names>C</given-names></name><name><surname>Stein</surname><given-names>DJ</given-names></name></person-group>
<article-title>Skin picking disorder</article-title>
<source/>Am J Psychiatry
<year>2012</year>
<volume>169</volume>
<fpage>1143</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">23128921</pub-id></element-citation>
</ref>
<ref id="B132">
<label>132</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Percinel</surname><given-names>I</given-names></name><name><surname>Yazici</surname><given-names>KU</given-names></name></person-group>
<article-title>Glutamatergic dysfunction in skin-picking disorder: treatment of a pediatric patient with N-acetylcysteine</article-title>
<source/>J Clin Psychopharmacol
<year>2014</year>
<volume>34</volume>
<fpage>772</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="pmid">25203471</pub-id></element-citation>
</ref>
<ref id="B133">
<label>133</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Silva-Netto</surname><given-names>R</given-names></name><name><surname>Jesus</surname><given-names>G</given-names></name><name><surname>Nogueira</surname><given-names>M</given-names></name><name><surname>Tavares</surname><given-names>H</given-names></name></person-group>
<article-title>N-acetylcysteine in the treatment of skin-picking disorder</article-title>
<source/>Rev Bras Psiquiatr
<year>2014</year>
<volume>36</volume>
<fpage>101</fpage>
</element-citation>
</ref>
<ref id="B134">
<label>134</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Berk</surname><given-names>M</given-names></name><name><surname>Jeavons</surname><given-names>S</given-names></name><name><surname>Dean</surname><given-names>OM</given-names></name><name><surname>Dodd</surname><given-names>S</given-names></name><name><surname>Moss</surname><given-names>K</given-names></name><name><surname>Gama</surname><given-names>CS</given-names></name><etal></etal></person-group>
<article-title>Nail-biting stuff? The effect of N-acetyl cysteine on nail-biting</article-title>
<source/>CNS Spectr
<year>2009</year>
<volume>14</volume>
<fpage>357</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="pmid">19773711</pub-id></element-citation>
</ref>
<ref id="B135">
<label>135</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yazici</surname><given-names>KU</given-names></name><name><surname>Percinel</surname><given-names>I</given-names></name></person-group>
<article-title>N-acetylcysteine augmentation in children and adolescents diagnosed with treatment-resistant obsessive-compulsive disorder: case series</article-title>
<source/>J Clin Psychopharmacol
<year>2015</year>
<volume>35</volume>
<fpage>486</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">26066338</pub-id></element-citation>
</ref>
<ref id="B136">
<label>136</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lafleur</surname><given-names>DL</given-names></name><name><surname>Pittenger</surname><given-names>C</given-names></name><name><surname>Kelmendi</surname><given-names>B</given-names></name><name><surname>Gardner</surname><given-names>T</given-names></name><name><surname>Wasylink</surname><given-names>S</given-names></name><name><surname>Malison</surname><given-names>RT</given-names></name><etal></etal></person-group>
<article-title>N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder</article-title>
<source/>Psychopharmacology (Berl)
<year>2006</year>
<volume>184</volume>
<fpage>254</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">16374600</pub-id></element-citation>
</ref>
<ref id="B137">
<label>137</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Politi</surname><given-names>P</given-names></name><name><surname>Rocchetti</surname><given-names>M</given-names></name><name><surname>Emanuele</surname><given-names>E</given-names></name><name><surname>Rondanelli</surname><given-names>M</given-names></name><name><surname>Barale</surname><given-names>F</given-names></name></person-group>
<article-title>Randomized placebo-controlled trials of omega-3 polyunsaturated fatty acids in psychiatric disorders: a review of the current literature</article-title>
<source/>Curr Drug Discov Technol
<year>2013</year>
<volume>10</volume>
<fpage>245</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="pmid">21838664</pub-id></element-citation>
</ref>
<ref id="B138">
<label>138</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Prior</surname><given-names>PL</given-names></name><name><surname>Galduróz</surname><given-names>JC</given-names></name></person-group>
<article-title>(N-3) Fatty acids: molecular role and clinical uses in psychiatric disorders</article-title>
<source/>Adv Nutr
<year>2012</year>
<volume>3</volume>
<fpage>257</fpage>
<lpage>65</lpage>
<pub-id pub-id-type="pmid">22585900</pub-id></element-citation>
</ref>
<ref id="B139">
<label>139</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Layé</surname><given-names>S</given-names></name></person-group>
<article-title>Polyunsaturated fatty acids, neuroinflammation and well being</article-title>
<source/>Prostaglandins Leukot Essent Fatty Acids
<year>2010</year>
<volume>82</volume>
<fpage>295</fpage>
<lpage>303</lpage>
<pub-id pub-id-type="pmid">20227866</pub-id></element-citation>
</ref>
<ref id="B140">
<label>140</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mischoulon</surname><given-names>D</given-names></name><name><surname>Freeman</surname><given-names>MP</given-names></name></person-group>
<article-title>Omega-3 fatty acids in psychiatry</article-title>
<source/>Psychiatr Clin North Am
<year>2013</year>
<volume>36</volume>
<fpage>15</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="pmid">23538073</pub-id></element-citation>
</ref>
<ref id="B141">
<label>141</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Green</surname><given-names>P</given-names></name><name><surname>Hermesh</surname><given-names>H</given-names></name><name><surname>Monselise</surname><given-names>A</given-names></name><name><surname>Marom</surname><given-names>S</given-names></name><name><surname>Presburger</surname><given-names>G</given-names></name><name><surname>Weizman</surname><given-names>A</given-names></name></person-group>
<article-title>Red cell membrane omega-3 fatty acids are decreased in nondepressed patients with social anxiety disorder</article-title>
<source/>Eur Neuropsychopharmacol
<year>2006</year>
<volume>16</volume>
<fpage>107</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="pmid">16243493</pub-id></element-citation>
</ref>
<ref id="B142">
<label>142</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>JJ</given-names></name><name><surname>Galfalvy</surname><given-names>HC</given-names></name><name><surname>Cooper</surname><given-names>TB</given-names></name><name><surname>Oquendo</surname><given-names>MA</given-names></name><name><surname>Grunebaum</surname><given-names>MF</given-names></name><name><surname>Mann</surname><given-names>JJ</given-names></name><etal></etal></person-group>
<article-title>Omega-3 polyunsaturated fatty acid (PUFA) status in major depressive disorder with comorbid anxiety disorders</article-title>
<source/>J Clin Psychiatry
<year>2013</year>
<volume>74</volume>
<fpage>732</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">23945451</pub-id></element-citation>
</ref>
<ref id="B143">
<label>143</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ross</surname><given-names>BM</given-names></name></person-group>
<article-title>Omega-3 polyunsaturated fatty acids and anxiety disorders</article-title>
<source/>Prostaglandins Leukot Essent Fatty Acids
<year>2009</year>
<volume>81</volume>
<fpage>309</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="pmid">19906519</pub-id></element-citation>
</ref>
<ref id="B144">
<label>144</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fux</surname><given-names>M</given-names></name><name><surname>Benjamin</surname><given-names>J</given-names></name><name><surname>Nemets</surname><given-names>B</given-names></name></person-group>
<article-title>A placebo-controlled cross-over trial of adjunctive EPA in OCD</article-title>
<source/>J Psychiatr Res
<year>2004</year>
<volume>38</volume>
<fpage>323</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">15003438</pub-id></element-citation>
</ref>
<ref id="B145">
<label>145</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matsuoka</surname><given-names>Y</given-names></name><name><surname>Nishi</surname><given-names>D</given-names></name><name><surname>Hamazaki</surname><given-names>K</given-names></name><name><surname>Yonemoto</surname><given-names>N</given-names></name><name><surname>Matsumura</surname><given-names>K</given-names></name><name><surname>Noguchi</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Docosahexaenoic acid for selective prevention of posttraumatic stress disorder among severely injured patients: a randomized, placebo-controlled trial</article-title>
<source/>J Clin Psychiatry
<year>2015</year>
<volume>76</volume>
<fpage>e1015</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="pmid">26335087</pub-id></element-citation>
</ref>
<ref id="B146">
<label>146</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hughes</surname><given-names>RN</given-names></name><name><surname>Lowther</surname><given-names>CL</given-names></name><name><surname>van Nobelen</surname><given-names>M</given-names></name></person-group>
<article-title>Prolonged treatment with vitamins C and E separately and together decreases anxiety-related open-field behavior and acoustic startle in hooded rats</article-title>
<source/>Pharmacol Biochem Behav
<year>2011</year>
<volume>97</volume>
<fpage>494</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">21036190</pub-id></element-citation>
</ref>
<ref id="B147">
<label>147</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Angrini</surname><given-names>MA</given-names></name><name><surname>Leslie</surname><given-names>JC</given-names></name></person-group>
<article-title>Vitamin C attenuates the physiological and behavioural changes induced by long-term exposure to noise</article-title>
<source/>Behav Pharmacol
<year>2012</year>
<volume>23</volume>
<fpage>119</fpage>
<lpage>25</lpage>
<pub-id pub-id-type="pmid">22198322</pub-id></element-citation>
</ref>
<ref id="B148">
<label>148</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Puty</surname><given-names>B</given-names></name><name><surname>Maximino</surname><given-names>C</given-names></name><name><surname>Brasil</surname><given-names>A</given-names></name><name><surname>da Silva</surname><given-names>WL</given-names></name><name><surname>Gouveia</surname><given-names>A</given-names><suffix>Jr</suffix></name><name><surname>Oliveira</surname><given-names>KR</given-names></name><etal></etal></person-group>
<article-title>Ascorbic acid protects against anxiogenic-like effect induced by methylmercury in zebrafish: action on the serotonergic system</article-title>
<source/>Zebrafish
<year>2014</year>
<volume>11</volume>
<fpage>365</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="pmid">24979594</pub-id></element-citation>
</ref>
<ref id="B149">
<label>149</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Oliveira</surname><given-names>IJ</given-names></name><name><surname>de Souza</surname><given-names>VV</given-names></name><name><surname>Motta</surname><given-names>V</given-names></name><name><surname>Da-Silva</surname><given-names>SL</given-names></name></person-group>
<article-title>Effects of oral vitamin C supplementation on anxiety in students: a double-blind, randomized, placebo-controlled trial</article-title>
<source/>Pak J Biol Sci
<year>2015</year>
<volume>18</volume>
<fpage>11</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">26353411</pub-id></element-citation>
</ref>
<ref id="B150">
<label>150</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Levitan</surname><given-names>MN</given-names></name><name><surname>Papelbaum</surname><given-names>M</given-names></name><name><surname>Nardi</surname><given-names>AE</given-names></name></person-group>
<article-title>Profile of agomelatine and its potential in the treatment of generalized anxiety disorder</article-title>
<source/>Neuropsychiatr Dis Treat
<year>2015</year>
<volume>11</volume>
<fpage>1149</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="pmid">25999720</pub-id></element-citation>
</ref>
<ref id="B151">
<label>151</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bozzatello</surname><given-names>P</given-names></name><name><surname>Brignolo</surname><given-names>E</given-names></name><name><surname>De Grandi</surname><given-names>E</given-names></name><name><surname>Bellino</surname><given-names>S</given-names></name></person-group>
<article-title>Supplementation with omega-3 fatty acids in psychiatric disorders: a review of literature data</article-title>
<source/>J Clin Med
<year>2016</year>
<volume>5</volume>
<issue>8</issue>
<fpage>E67</fpage>
<comment>doi: 10.3390/jcm5080067</comment>
<pub-id pub-id-type="pmid">27472373</pub-id></element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<table-wrap id="t01" position="float">
<label>Table 1</label>
<caption>
<title>Anxiolytic-like effects of mult-itarget compounds: preclinical studies</title>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Compound/dose</th>
<th align="left" colspan="1" rowspan="1">Treatment duration</th>
<th align="left" colspan="1" rowspan="1">Species</th>
<th align="left" colspan="1" rowspan="1">Behavioral tests</th>
<th align="left" colspan="1" rowspan="1">Effects</th>
<th align="left" colspan="1" rowspan="1">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Agomelatine</td>
<td align="left" colspan="1" rowspan="1">
</td>
<td align="left" colspan="1" rowspan="1">
</td>
<td align="left" colspan="1" rowspan="1">
</td>
<td align="left" colspan="1" rowspan="1">
</td>
<td align="left" colspan="1" rowspan="1">
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    2.5-80 mg/kg, i.p.</td>
<td align="left" colspan="1" rowspan="1">Acute</td>
<td align="left" colspan="1" rowspan="1">Rats</td>
<td align="left" colspan="1" rowspan="1">EPM , SI, UV, VCT</td>
<td align="left" colspan="1" rowspan="1">Anxiolytic</td>
<td align="left" colspan="1" rowspan="1">Millan et al.<xref ref-type="bibr" rid="B65">65</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    10-75 mg/kg, i.p.</td>
<td align="left" colspan="1" rowspan="1">Acute</td>
<td align="left" colspan="1" rowspan="1">Rats</td>
<td align="left" colspan="1" rowspan="1">Conditioned footshock-induced UV, EPM, VCT,</td>
<td align="left" colspan="1" rowspan="1">Anxiolytic</td>
<td align="left" colspan="1" rowspan="1">Papp et al.<xref ref-type="bibr" rid="B66">66</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    20-40 mg/kg, i.p.Acute</td>
<td align="left" colspan="1" rowspan="1">Rats</td>
<td align="left" colspan="1" rowspan="1">EPM, NIH, PD, SSWS</td>
<td align="left" colspan="1" rowspan="1">Anxiolytic in the EPM</td>
<td align="left" colspan="1" rowspan="1">Loiseau et al.<xref ref-type="bibr" rid="B64">64</xref>
</td>
<td colspan="1" rowspan="1">
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    40-50 mg/kg, i.p.</td>
<td align="left" colspan="1" rowspan="1">Chronic</td>
<td align="left" colspan="1" rowspan="1">Rats</td>
<td align="left" colspan="1" rowspan="1">EPM, FST</td>
<td align="left" colspan="1" rowspan="1">Prevented prenatal restraint-induced anxiety-like behavior in the EPM</td>
<td align="left" colspan="1" rowspan="1">Morley-Fletcher et al.<xref ref-type="bibr" rid="B58">58</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">NAC</td>
<td align="left" colspan="1" rowspan="1">
</td>
<td align="left" colspan="1" rowspan="1">
</td>
<td align="left" colspan="1" rowspan="1">
</td>
<td align="left" colspan="1" rowspan="1">
</td>
<td align="left" colspan="1" rowspan="1">
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    50 mg/kg, i.p.,</td>
<td align="left" colspan="1" rowspan="1">Acute</td>
<td align="left" colspan="1" rowspan="1">Mice</td>
<td align="left" colspan="1" rowspan="1">MBB</td>
<td align="left" colspan="1" rowspan="1">Inhibited marble-burying behavior</td>
<td align="left" colspan="1" rowspan="1">Egashira et al.<xref ref-type="bibr" rid="B67">67</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    150 mg/kg, i.p.</td>
<td align="left" colspan="1" rowspan="1">10 days</td>
<td align="left" colspan="1" rowspan="1">Rats</td>
<td align="left" colspan="1" rowspan="1">EPM, OF, SI</td>
<td align="left" colspan="1" rowspan="1">Reversed valproate-induced anxiety-like behavior and social interaction deficit</td>
<td align="left" colspan="1" rowspan="1">Chen et al.<xref ref-type="bibr" rid="B68">68</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    30 or 60 mg/kg, i.p.</td>
<td align="left" colspan="1" rowspan="1">11 days</td>
<td align="left" colspan="1" rowspan="1">Mice</td>
<td align="left" colspan="1" rowspan="1">HB, SP</td>
<td align="left" colspan="1" rowspan="1">Prevented rhythm disruption-induced anxiety in the HB</td>
<td align="left" colspan="1" rowspan="1">Pilz et al.<xref ref-type="bibr" rid="B69">69</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    0.1, 1.0 and 10 mg/L of tank water</td>
<td align="left" colspan="1" rowspan="1">Acute</td>
<td align="left" colspan="1" rowspan="1">Zebrafish</td>
<td align="left" colspan="1" rowspan="1">L/D, NT</td>
<td align="left" colspan="1" rowspan="1">Anxiolytic in the L/D, prevented acute stressor-induced anxiety-like behavior in NT</td>
<td align="left" colspan="1" rowspan="1">Mocelin et al.<xref ref-type="bibr" rid="B70">70</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    60-150 mg/kg, i.p.</td>
<td align="left" colspan="1" rowspan="1">Acute and subacute (4 days)</td>
<td align="left" colspan="1" rowspan="1">Mice</td>
<td align="left" colspan="1" rowspan="1">ETM, HB, L/D, OF, SI, SIH</td>
<td align="left" colspan="1" rowspan="1">Anxiolytic (except at the elevated T-maze).</td>
<td align="left" colspan="1" rowspan="1">Santos et al.<xref ref-type="bibr" rid="B71">71</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Omega-3</td>
<td align="left" colspan="1" rowspan="1">
</td>
<td align="left" colspan="1" rowspan="1">
</td>
<td align="left" colspan="1" rowspan="1">
</td>
<td align="left" colspan="1" rowspan="1">
</td>
<td align="left" colspan="1" rowspan="1">
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    Diet supplemented with DHA</td>
<td align="left" colspan="1" rowspan="1">Chronic</td>
<td align="left" colspan="1" rowspan="1">Mice</td>
<td align="left" colspan="1" rowspan="1">OF, L/D, MWM</td>
<td align="left" colspan="1" rowspan="1">Anxiolytic in the L/D</td>
<td align="left" colspan="1" rowspan="1">Carrié et al.<xref ref-type="bibr" rid="B72">72</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    Diet supplemented with different combinations of omega-3 PUFA</td>
<td align="left" colspan="1" rowspan="1">Chronic</td>
<td align="left" colspan="1" rowspan="1">Rats</td>
<td align="left" colspan="1" rowspan="1">EPM, OF</td>
<td align="left" colspan="1" rowspan="1">Attenuated i.c.v. IL-1 beta-induced anxiety.</td>
<td align="left" colspan="1" rowspan="1">Song et al.<xref ref-type="bibr" rid="B73">73</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    Diet supplemented with different proportions of ethyl-EPA</td>
<td align="left" colspan="1" rowspan="1">Chronic</td>
<td align="left" colspan="1" rowspan="1">Rats</td>
<td align="left" colspan="1" rowspan="1">EPM, OF</td>
<td align="left" colspan="1" rowspan="1">Attenuated the i.c.v. IL-1 beta-induced anxiety</td>
<td align="left" colspan="1" rowspan="1">Song et al.<xref ref-type="bibr" rid="B74">74</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    Diet supplemented with EPA + DHA</td>
<td align="left" colspan="1" rowspan="1">Chronic</td>
<td align="left" colspan="1" rowspan="1">Rats</td>
<td align="left" colspan="1" rowspan="1">EPM, modified FST, MWM</td>
<td align="left" colspan="1" rowspan="1">Counteracted restraint-induced anxiety</td>
<td align="left" colspan="1" rowspan="1">Ferraz et al.<xref ref-type="bibr" rid="B75">75</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    Diet supplemented with long-chain omega-3 PUFA</td>
<td align="left" colspan="1" rowspan="1">Chronic</td>
<td align="left" colspan="1" rowspan="1">Grey mouse lemur (<italic>Microcebus murinus</italic>)</td>
<td align="left" colspan="1" rowspan="1">OF</td>
<td align="left" colspan="1" rowspan="1">Anxiolytic</td>
<td align="left" colspan="1" rowspan="1">Vinot et al.<xref ref-type="bibr" rid="B76">76</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    Diet supplemented with EPA + DHA</td>
<td align="left" colspan="1" rowspan="1">Chronic</td>
<td align="left" colspan="1" rowspan="1">Rats</td>
<td align="left" colspan="1" rowspan="1">Avoidance conditioning, EPM</td>
<td align="left" colspan="1" rowspan="1">Prevented restraint stress-induced anxiety</td>
<td align="left" colspan="1" rowspan="1">Pérez et al.<xref ref-type="bibr" rid="B77">77</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    10:1 omega-6/omega-3 diet supplemented with DHA for three generations</td>
<td align="left" colspan="1" rowspan="1">Chronic</td>
<td align="left" colspan="1" rowspan="1">Mice</td>
<td align="left" colspan="1" rowspan="1">EPM, OF</td>
<td align="left" colspan="1" rowspan="1">Anxiolytic in third generation male offspring</td>
<td align="left" colspan="1" rowspan="1">Jašarević et al.<xref ref-type="bibr" rid="B78">78</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    Diet supplemented with long-chain omega-3 PUFA</td>
<td align="left" colspan="1" rowspan="1">Chronic</td>
<td align="left" colspan="1" rowspan="1">Grey mouse lemur (<italic>Microcebus murinus</italic>)</td>
<td align="left" colspan="1" rowspan="1">OF, Barnes maze</td>
<td align="left" colspan="1" rowspan="1">Anxiolytic</td>
<td align="left" colspan="1" rowspan="1">Pifferi et al.<xref ref-type="bibr" rid="B79">79</xref>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TFN01t01">
<p>DHA = docosahexaenoic acid; EPA = eicosapentaenoic acid; EPM = elevated plus maze; ETM = elevated T-maze; FST = forced swim test; HB = hole-board; i.c.v = intracerebroventricular; IL = interleukin; i.p. = intraperitoneal; L/D = light/dark; MBB = marble-burying behavior; MWM = Morris water maze; NAC = N-acetylcysteine; NIH = novelty-induced hypophagia; NOR = novel object recognition test; NT = novel tank; OF = open field; PD = punished drinking test; PUFA = polyunsaturated fatty acid; SI = social interaction; SIH = stress-induced hyperthermia; SP = social preference; SSWS = safety signal withdrawal schedule (operant conflict procedure); UV = ultrasonic vocalization test; VCT = vogel conflict test.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="t02" position="float">
<label>Table 2</label>
<caption>
<title>Anxiolytic effects of multitarget compounds: clinical trials</title>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Compound/disorder</th>
<th align="left" colspan="1" rowspan="1">Study design</th>
<th align="left" colspan="1" rowspan="1">Study size</th>
<th align="left" colspan="1" rowspan="1">Daily dose and treatment duration</th>
<th align="left" colspan="1" rowspan="1">Main measures/ instruments</th>
<th align="left" colspan="1" rowspan="1">Results</th>
<th align="left" colspan="1" rowspan="1">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Agomelatine</td>
<td align="left" colspan="1" rowspan="1">
</td>
<td align="left" colspan="1" rowspan="1">
</td>
<td align="left" colspan="1" rowspan="1">
</td>
<td align="left" colspan="1" rowspan="1">
</td>
<td align="left" colspan="1" rowspan="1">
</td>
<td align="left" colspan="1" rowspan="1">
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    GAD</td>
<td align="left" colspan="1" rowspan="1">RDBCT</td>
<td align="center" colspan="1" rowspan="1">121</td>
<td align="left" colspan="1" rowspan="1">25-50 mg, 12 weeks</td>
<td align="left" colspan="1" rowspan="1">CGI, HARS, LSEQ, SDS</td>
<td align="left" colspan="1" rowspan="1">Anxiolytic</td>
<td align="left" colspan="1" rowspan="1">Stein et al.<xref ref-type="bibr" rid="B80">80</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    GAD</td>
<td align="left" colspan="1" rowspan="1">Open-label treatment followed by a multicenter RDBCT</td>
<td align="center" colspan="1" rowspan="1">477</td>
<td align="left" colspan="1" rowspan="1">25-50 mg, 16 weeks (open-label) followed by 26 weeks (RDBCT)</td>
<td align="left" colspan="1" rowspan="1">CGI, DESS, HAD, HARS, LSEQ, SDS</td>
<td align="left" colspan="1" rowspan="1">Anxiolytic and well-tolerated in long-term treatment. Superior to placebo in preventing relapse.</td>
<td align="left" colspan="1" rowspan="1">Stein et al.<xref ref-type="bibr" rid="B81">81</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    GAD</td>
<td align="left" colspan="1" rowspan="1">Multicenter, RDBCT</td>
<td align="center" colspan="1" rowspan="1">412</td>
<td align="left" colspan="1" rowspan="1">25-50 mg, 12 weeks</td>
<td align="left" colspan="1" rowspan="1">CGI, HADS, LSEQ, SDS</td>
<td align="left" colspan="1" rowspan="1">Anxiolytic effect similar to escitalopram, with lower adverse events incidence.</td>
<td align="left" colspan="1" rowspan="1">Stein et al.<xref ref-type="bibr" rid="B82">82</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    GAD</td>
<td align="left" colspan="1" rowspan="1">RDBCT</td>
<td align="center" colspan="1" rowspan="1">412</td>
<td align="left" colspan="1" rowspan="1">10-25 mg, 12 weeks</td>
<td align="left" colspan="1" rowspan="1">HARS</td>
<td align="left" colspan="1" rowspan="1">Anxiolytic, placebo-agomelatine difference greater with the higher dose.</td>
<td align="left" colspan="1" rowspan="1">Stein et al.<xref ref-type="bibr" rid="B83">83</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">NAC</td>
<td align="left" colspan="1" rowspan="1">
</td>
<td align="left" colspan="1" rowspan="1">
</td>
<td align="left" colspan="1" rowspan="1">
</td>
<td align="left" colspan="1" rowspan="1">
</td>
<td align="left" colspan="1" rowspan="1">
</td>
<td align="left" colspan="1" rowspan="1">
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    TTM</td>
<td align="left" colspan="1" rowspan="1">RDBCT</td>
<td align="center" colspan="1" rowspan="1">50</td>
<td align="left" colspan="1" rowspan="1">1,200-2,400 mg, 12 weeks</td>
<td align="left" colspan="1" rowspan="1">CGI, HARS MGH-HPS, PITS</td>
<td align="left" colspan="1" rowspan="1">Reduced hair- pulling</td>
<td align="left" colspan="1" rowspan="1">Grant et al.<xref ref-type="bibr" rid="B84">84</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    OCD (refractory to SRI)</td>
<td align="left" colspan="1" rowspan="1">RDBCT</td>
<td align="center" colspan="1" rowspan="1">39</td>
<td align="left" colspan="1" rowspan="1">Initially 600 mg, doubling weekly to a maximum dose of 2,400 mg (add-on treatment to SRI), 12 weeks</td>
<td align="left" colspan="1" rowspan="1">CGI-S, Y-BOCS</td>
<td align="left" colspan="1" rowspan="1">Improved mean CGI-S and Y-BOCS scale scores</td>
<td align="left" colspan="1" rowspan="1">Afshar et al.<xref ref-type="bibr" rid="B85">85</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    Chronic nail biting</td>
<td align="left" colspan="1" rowspan="1">RDBCT</td>
<td align="center" colspan="1" rowspan="1">25</td>
<td align="left" colspan="1" rowspan="1">800 mg, 2 months</td>
<td align="left" colspan="1" rowspan="1">Nail length</td>
<td align="left" colspan="1" rowspan="1">Decreased nail biting over the short term</td>
<td align="left" colspan="1" rowspan="1">Ghanizadeh et al.<xref ref-type="bibr" rid="B86">86</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    OCD</td>
<td align="left" colspan="1" rowspan="1">RDBCT</td>
<td align="center" colspan="1" rowspan="1">44</td>
<td align="left" colspan="1" rowspan="1">3,000 mg (add-on treatment), 16 weeks</td>
<td align="left" colspan="1" rowspan="1">Y-BOCS</td>
<td align="left" colspan="1" rowspan="1">Decreased Y-BOCS score</td>
<td align="left" colspan="1" rowspan="1">Sarris et al.<xref ref-type="bibr" rid="B87">87</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    PTSD and SUD</td>
<td align="left" colspan="1" rowspan="1">RDBCT</td>
<td align="center" colspan="1" rowspan="1">35</td>
<td align="left" colspan="1" rowspan="1">2,400 mg, 8 weeks</td>
<td align="left" colspan="1" rowspan="1">CAPS, PCL-M, VAS</td>
<td align="left" colspan="1" rowspan="1">Improved PTSD and craving</td>
<td align="left" colspan="1" rowspan="1">Back et al.<xref ref-type="bibr" rid="B88">88</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    Skin-picking disorder</td>
<td align="left" colspan="1" rowspan="1">RDBCT</td>
<td align="center" colspan="1" rowspan="1">53</td>
<td align="left" colspan="1" rowspan="1">1,200-3,000 mg, 12 weeks</td>
<td align="left" colspan="1" rowspan="1">Measures of skin-picking severity: CGI-S and modified Y-BOCS</td>
<td align="left" colspan="1" rowspan="1">Decreased skin-picking</td>
<td align="left" colspan="1" rowspan="1">Grant et al.<xref ref-type="bibr" rid="B89">89</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    OCD</td>
<td align="left" colspan="1" rowspan="1">RDBCT</td>
<td align="center" colspan="1" rowspan="1">44</td>
<td align="left" colspan="1" rowspan="1">2,000 mg (add-on treatment to fluvoxamine), 10 weeks</td>
<td align="left" colspan="1" rowspan="1">Y-BOCS</td>
<td align="left" colspan="1" rowspan="1">Decreased scores in Y-BOCS</td>
<td align="left" colspan="1" rowspan="1">Paydary et al.<xref ref-type="bibr" rid="B90">90</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Omega-3</td>
<td align="left" colspan="1" rowspan="1">
</td>
<td align="left" colspan="1" rowspan="1">
</td>
<td align="left" colspan="1" rowspan="1">
</td>
<td align="left" colspan="1" rowspan="1">
</td>
<td align="left" colspan="1" rowspan="1">
</td>
<td align="left" colspan="1" rowspan="1">
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    Test anxiety</td>
<td align="left" colspan="1" rowspan="1">Placebo controlled trial</td>
<td align="center" colspan="1" rowspan="1">126</td>
<td align="left" colspan="1" rowspan="1">90 mg of α-linolenic acid (omega-3) and 360 mg of linoleic acid (omega-6 fatty acid), 3 weeks</td>
<td align="left" colspan="1" rowspan="1">Standardized rating scale</td>
<td align="left" colspan="1" rowspan="1">Improved variables associated with test anxiety</td>
<td align="left" colspan="1" rowspan="1">Yehuda et al.<xref ref-type="bibr" rid="B91">91</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    SUD</td>
<td align="left" colspan="1" rowspan="1">RDBCT</td>
<td align="center" colspan="1" rowspan="1">24</td>
<td align="left" colspan="1" rowspan="1">3 g, 3 months</td>
<td align="left" colspan="1" rowspan="1">Modified version of the POMS (baseline and monthly)</td>
<td align="left" colspan="1" rowspan="1">Decreased anxiety scores progressively</td>
<td align="left" colspan="1" rowspan="1">Buydens-Branchey &amp; Branchey<xref ref-type="bibr" rid="B92">92</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    SUD</td>
<td align="left" colspan="1" rowspan="1">RDBCT</td>
<td align="center" colspan="1" rowspan="1">22</td>
<td align="left" colspan="1" rowspan="1">3 g, 3 months</td>
<td align="left" colspan="1" rowspan="1">Modified version of POMS</td>
<td align="left" colspan="1" rowspan="1">Decreased anxiety scores</td>
<td align="left" colspan="1" rowspan="1">Buydens-Branchey et al.<xref ref-type="bibr" rid="B93">93</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    Healthy young adults</td>
<td align="left" colspan="1" rowspan="1">RDBCT</td>
<td align="center" colspan="1" rowspan="1">68</td>
<td align="left" colspan="1" rowspan="1">2.5 g, 12 weeks</td>
<td align="left" colspan="1" rowspan="1">BAI, CES-D</td>
<td align="left" colspan="1" rowspan="1">Decreased anxiety</td>
<td align="left" colspan="1" rowspan="1">Kiecolt-Glaser et al.<xref ref-type="bibr" rid="B94">94</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    Alcoholic patients</td>
<td align="left" colspan="1" rowspan="1">RDBCT</td>
<td align="center" colspan="1" rowspan="1">31</td>
<td align="left" colspan="1" rowspan="1">60 mg EPA + 252 mg DHA, 3 weeks</td>
<td align="left" colspan="1" rowspan="1">PSS</td>
<td align="left" colspan="1" rowspan="1">Decreased anxiety/stress</td>
<td align="left" colspan="1" rowspan="1">Barbadoro et al.<xref ref-type="bibr" rid="B95">95</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    Early postmyocardial infarction</td>
<td align="left" colspan="1" rowspan="1">RDBCT</td>
<td align="center" colspan="1" rowspan="1">52</td>
<td align="left" colspan="1" rowspan="1">1 g + standard pharmacotherapy, 1 month</td>
<td align="left" colspan="1" rowspan="1">BDI, ESQ, STAI-S, STAI-T, used at the baseline (3rd day of acute myocardial infarction) and after one month</td>
<td align="left" colspan="1" rowspan="1">Decreased anxiety (STAI-S)</td>
<td align="left" colspan="1" rowspan="1">Haberka et al.<xref ref-type="bibr" rid="B96">96</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    PMS</td>
<td align="left" colspan="1" rowspan="1">RDBCT</td>
<td align="center" colspan="1" rowspan="1">124</td>
<td align="left" colspan="1" rowspan="1">2 g, 3 months</td>
<td align="left" colspan="1" rowspan="1">VAS</td>
<td align="left" colspan="1" rowspan="1">Decreased anxiety severity and duration</td>
<td align="left" colspan="1" rowspan="1">Sohrabi et al.<xref ref-type="bibr" rid="B97">97</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">    Japanese accident survivors (at risk for developing PTSD)</td>
<td align="left" colspan="1" rowspan="1">RDBCT</td>
<td align="center" colspan="1" rowspan="1">83</td>
<td align="left" colspan="1" rowspan="1">1,470 mg DHA + 147 mg EPA, 12 weeks</td>
<td align="left" colspan="1" rowspan="1">Monitoring of heart rate and skin conductance, script-driven imagery of their traumatic event</td>
<td align="left" colspan="1" rowspan="1">Decreased heart rate</td>
<td align="left" colspan="1" rowspan="1">Matsumura et al.<xref ref-type="bibr" rid="B98">98</xref>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TFN01t02">
<p>BAI = Beck Anxiety Inventory; BDI = Beck Depression Inventory; CAPS = Clinician Administered PTSD Scale; CES-D = Center for Epidemiological Studies Depression Scale; CGI = Clinical Global Impression Scale; CGI-S = Clinical Global Impression - Severity of Illness; DESS = Discontinuation Emergent Signs and Symptoms checklist; DHA = docosahexaenoic acid; EPA = eicosapentaenoic acid; ESQ = Emotional State Questionnaire; GAD = generalized anxiety disorder; HAD = Hospital Anxiety and Depression Scale; HARS = Hamilton Anxiety Rating Scale; LSEQ = Leeds Sleep Evaluation Questionnaire; MGH-HPS = Massachusetts General Hospital Hair Pulling Scale; NAC = N-acetylcysteine; OCD = obsessive-compulsive disorder; PCL-M = PTSD Checklist-Military; PITS = Psychiatric Institute Trichotillomania Scale; PMS = premenstrual syndrome; POMS = Profiles of Mood States; PSS = Perceived Stress Scale; PTSD = posttraumatic stress disorder; PUFA = polyunsaturated fatty acid; RDBCT = randomized double-blind placebo-controlled trial; SDS = Sheehan Disability Scale; SRI = serotonin reuptake inhibitor; STAI-S = State-Trait Anxiety Inventory in a Specific Situation; STAI-T = State-Trait Anxiety Inventory as a General Trait; SUD = substance use disorder; TTM = trichotillomania; VAS = Visual Analog Scale; Y-BOCS = Yale-Brown Obsessive-Compulsive Scale.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>